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Introduction {#sec1}
============

The hematopoiesis of dendritic cells (DCs) is controlled by a network of transcription factors (TFs), including GATA2, SPI1 (PU.1), TCF4 (E2-2), ZEB2, IRF4, IRF8, and IKZF1 (IKAROS) ([@bib34]; [@bib10]). Critical roles have been demonstrated in humans for GATA2 ([@bib12]), IRF8 ([@bib20]; [@bib6]), and IKZF1 ([@bib11]). DC potential traverses the phenotypic space of hematopoietic stem cells (HSCs), multipotent progenitors (MPPs), common myeloid progenitors (CMPs), lymphoid-primed multipotent progenitors (LMPPs), and granulocyte-macrophage progenitors (GMPs) ([@bib28], [@bib29]; [@bib21]). Single-cell cloning experiments demonstrate oligo- and unipotent differentiation pathways and highlight critical interactions between TFs such as SPI1 (PU.1) and IRF8 in priming and directing DC development ([@bib29]; [@bib53]; [@bib15]).

Functionally distinct populations of DCs arise directly from hematopoiesis itself ([@bib29]; [@bib47]; [@bib54]). Plasmacytoid DCs (pDCs) are distinct from myeloid or classical DCs (cDCs), comprising two subsets, cDC1s and cDC2s, evolutionarily conserved across mammalian species ([@bib18]; [@bib17]). DC potential is found in CD123^+^ regions of human GMPs ([@bib28]; [@bib21]), where most cells have unipotential fates for pDCs, cDC1s, or cDC2s ([@bib29]). These observations are more consistent with contemporary lineage-primed models of hematopoiesis in which cell fate specification occurs in the early stem and progenitor cell compartments and development progresses along increasingly stable unipotent trajectories ([@bib35]; [@bib37]; [@bib53]; [@bib15]; [@bib27]). However, the phenotypic identities of GMPs that contain discrete DC potentials leading to pDCs, cDC1s, and cDC2s in human have not been described.

Human cDC2s, hereafter referred to as CD1c^+^ DCs, comprise two subpopulations in peripheral blood (PB), one closer in gene expression and function to cDC1s and the other to monocytes ([@bib46]; [@bib56]; [@bib2]; [@bib25]; [@bib54]). However, it is not known if both types of CD1c^+^ DC arise from distinct lineage trajectories, differentially regulated by TFs, or whether they represent two alternative transcriptional states of a common lineage originating from the CD123^+^ GMP.

IRF8 plays a major role in DC development. In mice, it is required for normal development of cDC1s and pDCs ([@bib51]; [@bib16]; [@bib48]). Acting at multiple stages, it balances neutrophil, monocyte, and DC fate in combination with the TFs CEBPα and PU.1 ([@bib29]; [@bib15]; [@bib5]; [@bib26]). In common with other TFs regulated by super-enhancers, IRF8 effects are dose-dependent ([@bib1]).

We have previously described two humans with bi-allelic *IRF8* mutations (*IRF8*^*K108E/K108E*^ and *IRF8*^*R83C/R291Q*^) with a complete absence of monocytes and DCs ([@bib20]; [@bib6]). *K108E* mutation results in loss of nuclear localization and transcriptional activity, concomitant with decreased protein stability ([@bib43]). *R291Q* is orthologous to *R294*, mutated in the BXH2 Irf8-deficient mouse. *R83C* shows reduced nuclear translocation, and neither *R291Q* nor *R83C* is able to regulate the Ets-IRF composite element or interferon (IFN)-stimulated response element, although *R291Q* retains BATF-JUN interactions *in vitro* ([@bib6]). The heterozygous parents of these individuals, together with a new kindred affected by an intermediate autosomal-dominant phenotype caused by a frameshift at *V426*, provide an allelic series of IRF8 activity.

In the present study, we use *in vitro* cultures, single-cell analysis, and the series of human *IRF8* variants to resolve two discrete pathways of DC development differentially dependent upon IRF8, each forming distinct subsets of the CD1c^+^ DC population. The IRF8^hi^ pathway is linked to a classical pathway shared by cDC1s and pDCs. The IRF8^lo^ pathway is linked to the development of monocytes.

Results {#sec2}
=======

CD1c^+^DC Heterogeneity Is Evident in Human Bone Marrow {#sec2.1}
-------------------------------------------------------

We first sought to define CD1c^+^ DC heterogeneity in healthy control (HC) human PB by conventional flow cytometry. This revealed differential expression of monocyte-related antigens CD14 and CD163 and lymphoid-associated antigens CD5 and BTLA ([Figures 1](#fig1){ref-type="fig"}A, 1B, and [S1](#mmc1){ref-type="supplementary-material"}A) within the CD1c^+^ DC population. CD14 and CD5 expression marked the poles of a phenotypic continuum and CD163^+^BTLA^−^ and CD163^−^BTLA^+^ populations were identifiable within the CD14^−^CD5^−^ gate. Notably, CD14 expression on CD14^+^CD1c^+^ DCs is at least 1 log lower than on classical monocytes ([Figure S1](#mmc1){ref-type="supplementary-material"}B), which were excluded by CD88 expression. This continuum was mirrored at the transcriptomic level ([Figure 1](#fig1){ref-type="fig"}C) and was concordant with the differential expression of genes distinguishing DC2s from DC3s and DC3s from monocytes, as described previously ([@bib54]; [Figures S1](#mmc1){ref-type="supplementary-material"}C and S1D; [Table S1](#mmc1){ref-type="supplementary-material"}). In response to Toll-like receptor (TLR) stimulation, all fractions of CD1c^+^ DCs were able to elaborate interleukin-12 (IL-12), in contrast to monocytes. However, the monocyte-related cytokines IL-1β and IL-10 were produced by CD14^+^CD1c^+^ DCs ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}E).Figure 1CD1c^+^ DC Heterogeneity Is Evident in Human BM(A) Flow phenotyping of CD1c^+^ DCs from HC PB mononuclear cells (PBMCs) (representative example of n = 22), distinct from SIRPA^−^CD141^+^ cDC1s, CD123^+^CD303/4^+^ pDCs, and CD88^+^monocytes (Mono). CD14^+^CD163^+^BTLA^−^ (orange), CD14^−^CD163^+^BTLA^−^ (light orange), CD163^−^BTLA^+^CD5^−^ (light red), and CD163^−^BTLA^+^CD5^+^ (red) CD1c^+^ DC subsets are indicated.(B) 3D representation of CD14, CD5, and BTLA expression (flow cytometry) across the CD1c^+^ DC population. Heatmap shows expression of CD163.(C) PCA of NanoString gene expression profiling of fluorescence-activated cell sorting (FACS)-purified DC subsets from n = 3 HC PBMCs. CD1c^+^ DCs were purified based on their expression of CD14, CD5, and BTLA (A).(D) Intracellular flow analysis of *in vitro* cytokine elaboration (percentage of positive cells) by PB monocytes (black) and CD1c^+^DC subsets CD14^+^ (orange), CD14^−^CD5^−^ (gray), and CD5^+^ (red) from n = 9 HC donors in response to 14-h stimulation with TLR agonists (CpG, poly(I:C), CL075, and lipopolysaccharide \[LPS\]). p values were derived from paired two-tailed t tests; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.005. Bars show mean ± SEM, and circles represent individual donors.(E and F) Representative examples of the flow profiling of DC subsets in human spleen (n = 3), dermis (n = 3) (E) and BM (n = 13) (F), gated as in (A). Histograms show CD163 and BTLA expression on CD14^+^ (orange), CD5^+^ (red) and CD14^−^CD5^−^ (gray) CD1c^+^ DCs.(G) tSNE visualization of the expression of TFs and surface markers across HC PB and BM lineage(lin, CD3,19,20,56,161)^-^HLA-DR^+^ cells by CyTOF analysis. Black gates indicate the CD1c^+^DC population distinct from CD88^+^monocytes, CLEC9A^+^cDC1 and CD303^+^pDC. Red and orange gates indicate expression of lymphocyte- or monocyte-associated antigens, respectively.(H) Hierarchical clustering of single-cell transcriptomes of mature DCs from BM using all protein-coding, non-cell-cycle genes. Marker genes were identified within SC3 with parameters p \< 0.01, area under the receiver operating characteristic curve (AUROC) \> 0.85; cluster 1, pDCs (*GZMB*, *JCHAIN*); cluster 2, monocytes (*S100A8*, *VCAN*); cluster 3, CD14^+^ DC3s (*HLA-DPB1*); cluster 5, cDC1s (*CD59*). The top rows show fluorescence intensity of surface antigens ("Antigens") from index-sorted cells, and "Phenotype" denotes their classification defined by surface markers.See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

CD5^+^ and CD14^+^ CD1c^+^ DC subsets, with differential CD163 expression, were present in HC spleen and dermis ([Figures 1](#fig1){ref-type="fig"}E, [S1](#mmc1){ref-type="supplementary-material"}F, and S1G). However, BTLA expression was much lower in spleen and only just detectable in dermis ([Figures 1](#fig1){ref-type="fig"}E and [S1](#mmc1){ref-type="supplementary-material"}H). Bone marrow (BM) also contained homologous populations, although BTLA was not well expressed in this tissue ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}F--S1H). To simultaneously interrogate PB and BM, the panel was extended using mass cytometry (cytometry by time of flight \[CyTOF\]). CD1c^+^ DCs were delineated by the expression of CD1c, CD2, FcεR1A, and IRF4, distinct from CD88^+^ monocytes and other DC subsets ([Figures 1](#fig1){ref-type="fig"}G, [S1](#mmc1){ref-type="supplementary-material"}H, and S1I; [Table S2](#mmc1){ref-type="supplementary-material"}). In both tissues, the CD5^+^ pole was apposed to a small SIGLEC6^+^AXL^+^ population (both BTLA^+^ in PB), while the CD14^+^ pole expressed monocyte-related antigens CD11b and CD36.

Index-sorted single-cell RNA sequencing (scRNA-seq) and unsupervised hierarchical clustering of mature DCs from HC BM confirmed that CD1c^+^ DCs were heterogeneous and transcriptionally distinct from monocytes ([Figures 1](#fig1){ref-type="fig"}H and [S1](#mmc1){ref-type="supplementary-material"}J; [Table S3](#mmc1){ref-type="supplementary-material"}). CD14^+^CD1c^+^ DCs (cluster 3, high *HLA-DPB1*) clustered separately from CD14^bright^ monocytes (cluster 2, marked by *S100A8*, *VCAN*) but shared some monocyte-related transcripts. In contrast, clusters 6--8, encompassing CD5^+^CD1c^+^ DCs, shared features with cDC1s (cluster 5, *CD59*).

These experiments defined a set of antigens marking heterogeneity of CD1c^+^ DCs in multiple tissues. Depending on the context, one or more antigens may be used to bisect the population into DCs enriched for lymphoid- (CD5 and BTLA) or monocyte-related (CD14 and CD163) markers. For consistency with recent literature, we will refer to CD163^−^ (CD5^+^ and CD5^−^) cells as DC2s (BTLA^+^ in PB) and CD163^+^ (CD14^+^ and CD14^−^) cells as DC3s (BTLA^−^ in PB) ([Figure S1](#mmc1){ref-type="supplementary-material"}M). The presence of a discrete population of DC3s in BM is consistent with a direct hematopoietic origin rather peripheral conversion of monocytes.

CD14 Expression Distinguishes Heterogeneous CD1c^+^ DC Subsets Generated *In Vitro* {#sec2.2}
-----------------------------------------------------------------------------------

The generation of CD1c^+^ DCs subsets has not been previously demonstrated by *in vitro* culture. To probe this potential in human progenitor and precursor subsets we tested a system containing stem cell factor (SCF), FLT3 ligand (FL) and granulocyte-macrophage-colony-stimulating factor (GM-CSF) with *Csf1*^−*/*−^ OP9 stromal cells to prevent overgrowth of monocytes ([@bib36]). It was possible to differentiate all primary DC subsets and some CD14^+^ monocytes in this system ([Figures 2](#fig2){ref-type="fig"}A and [S2](#mmc1){ref-type="supplementary-material"}A). The output was analyzed by at least two surface markers per subset. CD1c^+^ DCs were distinguished from monocytes by their expression of CD1c and CD2 and lack of CD88 ([Figures 2](#fig2){ref-type="fig"}A and 2B). Within the CD1c^+^DC compartment, CD163 was exclusively expressed by CD14^+^ cells, while CD5^+^ cells were contained within the CD14^−^ population. In this system, CD14 expression defined populations corresponding to PB DC2s (CD14^−^CD163^−^) and DC3 (CD14^+^CD163^+^) ([Figures 2](#fig2){ref-type="fig"}A and 2B). Culture-derived DCs and monocytes retained appropriate expression of TFs IRF4 and IRF8 ([Figure 2](#fig2){ref-type="fig"}C).Figure 2CD14 Expression Distinguishes between CD1c^+^DC Subsets Generated *In Vitro*(A) Gating strategy used to identify DCs and monocytes generated from HC BM CD34^+^ progenitors at day 21 (D21) of culture on OP9 in the presence of SCF, FL, and GM-CSF. A minimum of two antigens was used to define the following populations: CD141^+^CLEC9A^+^ cDC1s, CD123^+^CD303^+^CD304^+^ pDCs, CD2^+^CD1c^+^ DCs encompassing CD14^+^ and CD5^+^ populations, and CD14^+^CD1c^−^CD2^−^ monocytes.(B) Flow analysis of the expression of population-specific markers across *in vitro*-generated monocytes (black), CD14^+^ (orange), CD5^+^ (red), or CD5^−^ (pink) CD14^−^CD1c^+^ DCs as defined in (A).(C) Intracellular flow evaluation of the expression of IRF4 and IRF8 by PB and culture-derived monocytes and DCs, gated as shown in [Figure 1](#fig1){ref-type="fig"}A and (A), respectively.(D) Kinetics of DC culture output over 21 days plotted as the number of DCs or monocytes generated per CD34^+^ progenitor. n = 6 donors with minimum n = 3 at each time point. Dots and bars show mean and SEM.(E) Flow analysis of the expression of population-specific markers by FACS-purified PB monocytes and CD1c^+^ subsets at day 7 of culture.(F) Flow analysis of CD14 expression by FACS-purified PB CD1c^+^subsets at day 7 of culture. Histogram shows a representative example from n = 7 (CD14^−^ DC3 and CD5^−^ DC2) or n = 5 (CD5^+^ DC2) HC donors, summarized in the graph. Bars represent mean ± SEM. Circles represent individual donors. ^∗∗∗^p \< 0.005 by paired two-tailed t test.(G) PCA of NanoString gene expression of FACS-purified PB DCs ("PB") (n = 3) and DCs derived from BM CD34^+^ progenitors at D21 of culture ("C"; black outline) (n = 3) after removal of a "culture signature" generated by pairwise comparison of all PB versus all culture-generated cells.(H) Heatmap of *Z* scores of differentially expressed signature genes (NanoString) derived from pairwise comparisons of PB CD1c^+^ DC subsets and monocytes, shown next to the *Z* scores of expression of the same genes by culture-derived CD14^−^ and CD14^+^ DCs and monocytes.(I) Intracellular flow analysis of *in vitro* cytokine elaboration (percentage of positive cells) in response to TLR agonists, as described in [Figure 1](#fig1){ref-type="fig"}D, by CD14^+^CD1c^−^ monocytes (black bars), CD14^+^ DC3s (orange), and CD14^−^ DC2s (red) generated from n = 4 BM CD34^+^ progenitors at day 21 of culture. p values from paired two-tailed t tests; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.005. Bars show mean ± SEM.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Two observations suggested that CD1c^+^ DC subsets were generated independently of monocytes and of each other. First, CD1c^+^ DCs appeared early, ahead of monocytes ([Figure 2](#fig2){ref-type="fig"}D). Second, *ex vivo* PB CD1c^+^ DC subsets and monocytes remained stable in culture for 7 days and did not interconvert ([Figures 2](#fig2){ref-type="fig"}E and [S2](#mmc1){ref-type="supplementary-material"}B). Although some PB DCs gained CD14 expression *in vitro*, this was restricted to CD14^−^ (CD163^+^BTLA^−^) DC3s ([Figure 2](#fig2){ref-type="fig"}F). Thus, *in vitro*, CD14 functions as a more inclusive marker for DC3 than in fresh PB, where it marks only the pole of this phenotype. There was some loss of CD5 expression on DC2s *in vitro*, but this did not hamper the separation of DCs and monocytes by CD88, CD1c, CD2, and CD163, which all remained stable ([Figure 2](#fig2){ref-type="fig"}E).

The identity of *in-vitro*-generated DC2s, DC3s, and monocytes generated in this system was validated by transcriptomic and functional analyses. Principal-component analysis (PCA) of NanoString gene expression data showed that *in-vitro*-generated CD14^−^ DC2s and CD14^+^ DC3s were appropriately polarized relative to cDC1s and monocytes ([Figures 2](#fig2){ref-type="fig"}G and [S2](#mmc1){ref-type="supplementary-material"}C). Key signature transcripts of sorted PB DCs were also expressed in the corresponding cultured cells, including *BTLA*, *CD5*, and *HLA-DOB* in DC2s, *IL1B* in DC3s, and *ZBTB16* in monocytes ([Figure 2](#fig2){ref-type="fig"}H). Genes defining DC2s, DC3s, and monocytes ([@bib54]) were appropriately enriched in culture-derived populations ([Figures S2](#mmc1){ref-type="supplementary-material"}D and S2E), which also generated similar cytokine profiles to fresh PB DCs and monocytes on TLR stimulation ([Figures 2](#fig2){ref-type="fig"}I and [S2](#mmc1){ref-type="supplementary-material"}F).

High IRF8 Expression Defines LMPP-Associated DC Progenitors {#sec2.3}
-----------------------------------------------------------

This *in vitro* culture system was used to map DC potential in sorted fractions of human BM. In describing immature cells, the terms "progenitor" and "precursor" refer specifically to CD34^+^ and CD34^neg-int^ populations, respectively ([Table S4](#mmc1){ref-type="supplementary-material"}). Human DCs have previously been derived from classical myeloid progenitors (CMPs and GMPs), LMPPs, and CD123^+^ fractions of the GMP, which were included here for comparison. HSCs and MPPs were identified in CD38^lo^ gates ([Figure 3](#fig3){ref-type="fig"}A). CD10^+^ MLP and CD10^−^CD117^+^LMPP fractions were selected from the CD38^lo^CD45RA^+^ population. From the CD38^hi^ fraction were isolated CD45RA^−^CMP megakaryocyte-erythroid progenitors (MEPs) and CD45RA^+^ GMPs; CD10^+^ B and natural killer (NK) cell progenitors (B/NKs) were excluded. Within the GMP gate, surface expression of CD123 correlated with intracellular expression of IRF8, so CD123 negative-low, low, and intermediate fractions were gated prospectively for differentiation studies ([Figures 3](#fig3){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}A). Myeloid antigens CD33 and CD117 were expressed by a subset of CD123^neg-lo^ GMPs (GMP33^+^); CD33^−^CD117^−^ cells (GMP33^−^) within this gate were analyzed separately ([Figure 3](#fig3){ref-type="fig"}A). CD33 was also expressed by cells in the CD38^+^CD45RA^−^ compartment, known to contain CMP and MEP populations. CD33^+^ CMPs, with low expression of CD123, were sorted for comparison with CD33^−^ cells, predicted to contain mostly MEPs ([Figure S3](#mmc1){ref-type="supplementary-material"}B).Figure 3High IRF8 Expression Defines LMPP-Associated DC Progenitors(A) Flow gating strategy used to define and FACS-purify components of the CD34^+^ lin(CD3,14,16,19,20,7)^−^ compartment of human BM. HSC, hematopoietic stem cell; MPP, multipotent progenitor; MEP, megakaryocyte-erythroid progenitor; MLP, multilymphoid progenitor; LMPP, lymphoid-primed multipotent progenitor; CMP, common myeloid progenitor; GMP, granulocyte-macrophage progenitor.(B) Heatmap of intracellular IRF8 protein expression across CMP and GMP as defined in (A) (gate 1).(C) Monocyte and DC subset output from purified BM CD34^+^ populations at day 14 of culture gated as in [Figure 2](#fig2){ref-type="fig"}A. Populations were quantified as percentage of the total cells captured by all DC and monocyte gates. Absolute output is shown in [Figure S3](#mmc1){ref-type="supplementary-material"}C. Bulk CD34^+^ (22 experiments from 13 donors: 22;13); CMP (7;5); GMP33^+^ (7;6); LMPP (7;6); GMP33^−^ (6;6); GMP123^lo^ (3;3); GMP123^int^ (8;7) ([Table S4](#mmc1){ref-type="supplementary-material"}). Bars represent mean + SEM, and circles represent individual experiments. Significant differences in the proportional output of DC2s versus DC3s are indicated in red; ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗∗^p = 0.0001 (paired two-tailed t tests).(D) Unsupervised hierarchical clustering of transcriptomes of single cells within the GMP index-sorting gate, using all protein-coding, non-cell-cycle genes, independent of surface antigen expression. Marker genes for four clusters identified within the single-cell consensus clustering 3 (SC3) tool (p \< 0.1, AUROC \> 0.75) and *IRF8* are displayed. The top rows show fluorescence intensity of surface antigens from index-sorted cells. Flow annotation ("Flow annot") denotes the classification of cells by their surface phenotype ([Figures 3](#fig3){ref-type="fig"}A and [S3](#mmc1){ref-type="supplementary-material"}F).(E--G) tSNE visualization of the first 10 principal components (25% of total variance) of the transcriptomes of 262 CD34^+^ progenitor cells, independently of their surface phenotype. tSNE plots are shown annotated by (E), gate of origin from index-linked flow ([Figure S3](#mmc1){ref-type="supplementary-material"}F), or (F), 10 clusters from hierarchical clustering ([Figure S3](#mmc1){ref-type="supplementary-material"}J), Heatmaps (G) show flow surface antigen expression ("SA") and log2 expression of key DC TFs, *IRF8*, *TCF4*, *SPIB*, and *SPI1(PU.1)*, displayed across the tSNE plot (E and F). Black circles represent regions of high ("A") or low ("B") *IRF8* expression.(H and I) Diffusion map using all protein-coding, non-cell-cycle genes. (H) The key specifies the designated cluster color, identity, and cluster number from [Figure S3](#mmc1){ref-type="supplementary-material"}J. (I) *IRF8* expression. Diff Comp, diffusion component.(J) Violin plot of differential *IRF8* expression (log2) in progenitor clusters 5 (HSCs and MPPs), 1 (monocyte enriched), and 8 (DC related). ^∗∗^p = 0.001 by Mann-Whitney U.(K) Median fluorescence intensity (MFI) of intracellular IRF8 by flow analysis across gates identifying HC BM CD34^+^ HSCs and CD123^neg-lo^ CD33^+^ and CD123^int^ GMPs (n = 4) as defined in (A). ^∗^p = 0.028 by Mann-Whitney U.See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

DC potential was found in CMPs, GMPs, and LMPPs ([Figures 3](#fig3){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}C--S3E). pDCs, cDC1s, and DC2s mapped to LMPPs and CD33^−^, CD123^lo^, and CD123^int^ fractions of GMPs. DC3 potential was principally found in the CMP and CD123^neg-lo^GMP33^+^ fractions ([Figure 3](#fig3){ref-type="fig"}C). Although there was incomplete dissociation of DC2 from DC3 potential using this apposed-gate strategy, the output ratio of DC2s to DC3s ranged widely, from 17.65 in LMPPs to 0.45 in CD33^+^ CMPs ([Figure S3](#mmc1){ref-type="supplementary-material"}D). The relatively higher production of pDCs, cDC1s, and DC2s in the CD33^−^, CD123^lo^, and CD123^int^ GMP fractions was associated with increasing expression of IRF8 protein ([Figures 3](#fig3){ref-type="fig"}B, 3C, and [S3](#mmc1){ref-type="supplementary-material"}A). In contrast, DC3 potential localized predominantly to IRF8^lo^ progenitor fractions.

Transcriptional programming of the phenotype and culture potential seen in bulk populations was probed by index-sorted scRNA-seq of BM progenitors. Approximately equal numbers of CD34^+^ progenitors (excluding lineage^lo^CD10^+^ B/NK progenitors) were sorted from the quadrants defined by a bivariate plot of CD45RA and CD38 ([Figure S3](#mmc1){ref-type="supplementary-material"}F). scRNA-seq was performed with a modified SmartSeq2 protocol ([@bib41]). 262 out of 399 cells expressing 12,406 protein-coding genes passed quality control (QC) filters and cell-cycle-related transcripts were removed ([STAR Methods](#sec4){ref-type="sec"}; [Table S3](#mmc1){ref-type="supplementary-material"}). The computational pipeline, including dimensionality reduction, hierarchical clustering, and trajectory analyses, was unbiased and driven solely by gene expression data. Clusters were then mapped to cell-surface phenotype from indexed flow data.

Hierarchical clustering of cells within the GMP compartment revealed close relationships among CD33^−^, CD123^lo^, and CD123^int^ fractions of GMPs that formed a single *IRF8*^*hi*^ cluster (cluster 4) distinct from *IRF8*^*lo*^ GMP33^+^ clusters associated with monocyte (cluster 1), granulocyte (cluster 2), and early myeloid gene expression (*LYZ*, *ELANE*, and *MYC*, respectively) ([@bib39]; [@bib55]; [Figures 3](#fig3){ref-type="fig"}D and [S3](#mmc1){ref-type="supplementary-material"}G--S3I).

Broadening the analysis to include scRNA-seq of HSCs, MPPs, MEPs, CMPs, LMPPs, and MLPs ([Figure S3](#mmc1){ref-type="supplementary-material"}J), a single cluster contained cells with *in vitro* pDC, cDC1, and DC2 potential (cluster 8), marked by the expression of the DC-related genes *TCF4* and *RUNX* ([@bib9]; [@bib44]). Cluster 8 was adjacent to LMPPs (clusters 9 and 10) but remote from CMPs and GMP33^+^ (clusters 1 and 2) containing *in vitro* monocyte and DC3 potential.

Indexed phenotypes overlapped closely with cluster assignment visualized on t-distributed stochastic neighbor embedding (tSNE) plots ([Figures 3](#fig3){ref-type="fig"}E and 3F), although heterogeneity for DC-progenitor-related transcriptomes was revealed within phenotypic LMPPs. Phenotypic CD33^+^ CMPs and GMPs also contained two clusters associated with monocytic or granulocytic gene expression, respectively (cluster 1, marked by *LYZ* and *CSF1R*; and cluster 2, marked by *ELANE*, *CALR*, and *FAM46A*) ([@bib39]; [@bib40]; [Figure S3](#mmc1){ref-type="supplementary-material"}J). The majority of early progenitors did not express *IRF8*, but two signals were present: high expression associated with the DC cluster 8 and lower expression associated with the GMP33^+^ monocytic cluster 1. The *IRF8*^*hi*^ region ("A"; [Figure 3](#fig3){ref-type="fig"}G) was also marked by high CD2, *TCF4*, and *SPIB*, and the *IRF8*^*lo*^ region ("B"; [Figure 3](#fig3){ref-type="fig"}G) expressed high CD33 and *SPI1 (PU.1)*. A and B are linked to DC precursor populations as described subsequently in [Figure 4](#fig4){ref-type="fig"}.Figure 4Two Trajectories of DC Development Connect the Progenitor Compartment with Mature DCs(A) Flow gating strategy used to identify DCs and their precursors in BM, including CD141^+^ cDC1s; CD1c^+^ DCs; AXL^+^CD5^+^ cells composed of CD123^hi^CD11c^−^ (light pink) and CD123^int^CD11c^+^ (dark pink) fractions; CD2^+^ (light blue) and CD2^−^ (dark blue) pDCs; CD123^+^CD303/4^lo^ cells (turquoise); SIRPA/B^−^CD123^int^CD141^−^ (lightest purple) and CD141^lo^ (light purple) populations; and CD123^−^SIRPA/B CD34^int^ (brown), CD34^−^CD2^+^ (dark orange), and CD34^−^CD2^−^ (gray) precursors.(B) The output of *in vitro* culture of CD34^int^ DC precursors FACS-purified from BM using the gating strategy described in (A). Population-specific output is expressed as a proportion (%) of the total cells captured by all DC and monocyte gates. CD123^hi^303/4^lo^ (six experiments from four donors; 6;4); CD2^+^ pre-pDCs (5;3); CD123^hi^5^+^ (4;3); CD123^int^5^+^ (4;3); CD34^int^CD123^int^ (4;4); CD34^int^SIRPA^+^ (5;5); SIRPA^+^2^+^ (4;4); SIRPA^+^2^−^ (4;4). Bars represent mean + SEM, and circles represent individual experiments. Significant differences in the proportional output of DC2s versus DC3s (red) or DC3s versus monocyte (black) are indicated: ^∗^p \< 0.05; ^∗∗^p \< 0.01 (paired, two-tailed t test).(C) Flow gating strategy from (A) applied to lin^−^HLA-DR^+^ cells from HC BM fractionated by high, intermediate, and low CD34 expression, next to blood (columns) for comparison of antigen expression levels among progenitor, precursor, and mature populations. Individual DC lineages are ordered in rows.(D) Proliferative potential of FACS-purified DC and DC precursors estimated by CFSE dilution (see [STAR Methods](#sec4){ref-type="sec"}). CD34^+^progenitors and CD14^+^monocytes were included as positive and negative controls, respectively. The CFSE dilution histograms for each precursor are grouped and ordered according to their proposed position in the developmental trajectory for each DC lineage. Plots shown are representative of n = 3 experiments (summarized in [Figure S4](#mmc1){ref-type="supplementary-material"}H).(E and F) tSNE visualization of the first 20 principal components (explaining 35% total variance) of the transcriptomes of 244 single cells adaptively sampled from lin^−^HLA-DR^+^ CD34^neg-int^ precursor and mature DC populations of BM. tSNE plots are annotated by the gate of origin from index-linked flow (E) or by 15 clusters generated from hierarchical clustering of all protein-coding non-cell-cycle genes (F), independently of surface phenotype ([Figure S4](#mmc1){ref-type="supplementary-material"}K).(G) Heatmaps showing the expression of key surface antigens (SAs) (index-linked flow) or log2 gene expression of TFs and FLT3 (scRNA-seq) across the tSNE plot in (E) and (F). Black circles represent regions of high or low *IRF8* expression, marked A^l^ or B^l^, respectively. The differential expression patterns of these regions correspond to the patterns of regions "A" (IRF8^hi^CD123^int^GMP) and "B" (IRF8^lo^GMP33^+^) in [Figures 3](#fig3){ref-type="fig"}E--3G.(H and I) Diffusion map generated with all protein-coding, non-cell-cycle genes to infer pseudo-temporal ordering of cells and reconstruct lineage branching. (H) Cells are colored according to the hierarchical clusters generated in [Figure S4](#mmc1){ref-type="supplementary-material"}K. (I) *IRF8* expression (log2). Diff C, diffusion component.(J) Violin plot of differential *IRF8* expression (log2) in clusters 10 (SIRPA^+^34^int^) and 12 (early pre-DC2). ^∗∗^p \< 0.001 by Mann-Whitney U.(K and L) MFI of intracellular IRF8 by flow analysis across gates identifying BM 34^int^SIRPA^+^ pre-DC3s and pre-mono and CD123^hi^CD5^+^ early pre-DC2s (K) and CD5^+^ DC2s and CD5^−^ DC3s (L) (n = 4). ^∗^p = 0.028 by Mann-Whitney U.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Diffusion mapping represented clusters 1 (monocyte enriched), 6 (MEPs), and 8 (DCs) as divergent trajectories ([Figure 3](#fig3){ref-type="fig"}H; [Data S1](#mmc2){ref-type="supplementary-material"}). Clusters 9 and 10 (LMPPs) were located at the root of the DC trajectory and cluster 7 (early myeloid) at the root of the monocyte-gene enriched path. *IRF8* gene expression was statistically higher in the DC (cluster 8) compared to monocytic (cluster 1) trajectory ([Figures 3](#fig3){ref-type="fig"}I and 3J), as was the protein in corresponding indexed GMP populations (CD123^int^ versus CD33^+^) ([Figure 3](#fig3){ref-type="fig"}K).

Taken together, the *in vitro* culture data, scRNA-seq analysis, and flow phenotypes are consistent with the transition of pDC, cDC1, and DC2 potential through LMPP phenotype space to CD33^−^ and subsequently CD123^+^ fractions of the GMP, where IRF8 is highly expressed. In contrast, DC3 potential segregates predominantly with monocyte development through a different region of IRF8^lo^ GMP parameter space marked by CD33 expression.

Two Trajectories of DC Development Connect the Progenitor Compartment with Mature DCs {#sec2.4}
-------------------------------------------------------------------------------------

The forward trajectories of DC potential were mapped within the CD34^neg-int^ fraction of human BM. A gating strategy for these intermediate precursors was developed by iterative sorting and *in vitro* culture experiments ([Figure 4](#fig4){ref-type="fig"}A). After lineage^+^ (lin), CD34^+^, and mature DCs were removed, a population of AXL^+^CD5^+^ cells was identified, corresponding to pre-DC and "AS" DC populations previously described ([@bib47]; [@bib54]). AXL^+^ cells expressed CD123, and variable CD11c inversely correlated with IRF8 expression ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Under our experimental conditions, CD1c^−^ AXL^+^CD5^+^ cells contained only DC2 potential and were provisionally designated "early pre-DC2" (CD123^hi^CD11c^−^) and "pre-DC2" (CD123^int^CD11c^+^) ([Figures 4](#fig4){ref-type="fig"}B, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C). AXL^−^CD5^−^ cells were then gated on a bivariate plot of CD123 and SIRPA/B ([Figure 4](#fig4){ref-type="fig"}A). CD123^+^ cells (gate 1, teal) contained CD2^+^ and CD2^−^ fractions of CD303^hi^CD304^hi^ (CD303/4) pDCs, as previously reported ([@bib32]; [@bib8]). CD2^+^ cells had precursor characteristics, with higher CD34 expression, more proliferative potential, and phenotypic conversion to CD2^−^ pDCs *in vitro* ([Figures S4](#mmc1){ref-type="supplementary-material"}D--S4F). Tri-lineage potential was observed in the CD123^hi^CD303/4^lo^ gate (occupied by AXL^+^CD5^+^ cells, if not previously excluded) ([Figure S4](#mmc1){ref-type="supplementary-material"}G).

The CD123^neg-int^ SIRPA/B^−^ population (gate 2, dark purple) contained CD34^int^CD123^int^ cells enriched for cDC1 potential and adjacent to cells with low expression of the cDC1 marker CD141 ([Figures 4](#fig4){ref-type="fig"}A, 4B, and [S4](#mmc1){ref-type="supplementary-material"}B). These CD34^int^CD123^int^SIRPA^−^ "early pre-cDC1s" corresponded to CD34^lo^CD100^+^ cells with cDC1 potential detected previously ([@bib47]; [@bib54]), as confirmed by phenotypic and scRNA-seq analysis of PB, where these cells formed a distinct cluster marked by *NFIL3* ([Figures 4](#fig4){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}L--S4R).

SIRPA/B^+^ cells ([Figure 4](#fig4){ref-type="fig"}A, gate 3, dark brown) contained nearly all of the *in vitro* DC3 and monocyte potential. Among CD34^−^ SIRPA/B^+^ cells, CD2 expression enriched for DC3 potential (SIRPA^+^2^+^ "pre-DC3"). Under these experimental conditions, monocyte potential was relatively enriched in the CD2^−^ "pre-monocyte" fraction ([Figures 4](#fig4){ref-type="fig"}B, [S4](#mmc1){ref-type="supplementary-material"}B, and S4C).

This analysis demonstrated highly enriched single lineage DC potential within the CD34^int^ parameter space linking CD34^+^progenitors and CD34^−^ mature DCs. This may be illustrated by applying the gating described in [Figure 4](#fig4){ref-type="fig"}A to CD34 high, intermediate, and low fractions of lin^−^HLA-DR^+^ BM and PB cells ([Figure 4](#fig4){ref-type="fig"}C). Carboxyfluorescein succinimidyl ester (CFSE) dilution assays showed a loss of proliferative potential in keeping with the proposed maturation trajectories ([Figures 4](#fig4){ref-type="fig"}D and [S4](#mmc1){ref-type="supplementary-material"}H).

Seeking independent support for the proposed pathways, we performed scRNA-seq of CD34^int^ precursors and mature DCs from BM. Analysis used a computational pipeline driven only by gene expression data, independently indexed to the cell-surface phenotype used to define *in vitro* potential in the preceding experiments ([Figures 4](#fig4){ref-type="fig"}E--4J and [S4](#mmc1){ref-type="supplementary-material"}I--S4K). 244 of 260 cells with expression of 12,137 protein-coding, non-cell-cycle genes passed QC ([STAR Methods](#sec4){ref-type="sec"}; [Table S3](#mmc1){ref-type="supplementary-material"}).

Unsupervised hierarchical clustering generated clusters, annotated by their expression of known DC-subset-specific genes, that overlapped closely with indexed phenotypes (with the exception of CD123^int^SIRPA^−^ cells, which were too rare to be identified discretely; [Figures 4](#fig4){ref-type="fig"}E, 4F, and [S4](#mmc1){ref-type="supplementary-material"}I--S4K).

In tSNE visualization, DC2s and DC3s lay in adjacent halves of the CD1c^+^ DC population. DC2s (cluster 6), in the top half, were connected with cDC1s (cluster 11), AXL^+^ cells (cluster 12, expressing *SIGLEC6*), and pre-pDCs (clusters 3--5, expressing pDC genes *JCHAIN* and *MZB1*). DC3 (cluster 7, *CD14* and *VCAN*), in the lower half, were adjacent to CD34^int^ SIRPA^+^ cells (cluster 15, *VCAN*) and pre-monocytes (clusters 8 and 14, *MPO* and *AZU1*).

Two regions of the tSNE plot retained intermediate CD34 expression, marking immature precursor populations (A^**l**^ and B^**l**^,; [Figure 4](#fig4){ref-type="fig"}G). Their phenotypes, TF expression, and *in vitro* potentials corresponded very closely to the *IRF8*^*hi*^ and *IRF8*^*lo*^ regions identified in the progenitor analysis (A and B, respectively; [Figure 3](#fig3){ref-type="fig"}G). Specifically, A and A^**l**^ shared high *IRF8*, CD123, *TCF4*, and *SPIB* expression and gave rise to pDCs, cDC1s, and DC2 *in vitro*, while B and B^**l**^ expressed low amounts of *IRF8* but high CD33 and *SPI1(PU.1)* and generated predominantly DC3s and monocytes in culture. *FLT3* was expressed in all DC precursors, including SIRPA^+^2^+^ pre-DC3, but not SIRPA^+^2^−^, pre-monocytes ([Figure 4](#fig4){ref-type="fig"}G).

Diffusion mapping defined distinct trajectories for cDC1s (cluster 11), pDCs (clusters 1--5), DC2s and DC3s (clusters 6 and 7), and monocytes (clusters 8 and 9; [Figure 4](#fig4){ref-type="fig"}H; [Data S2](#mmc3){ref-type="supplementary-material"}). The DC2 trajectory originated in the CD123^+^CD11c^−^CD5^+^ early pre-DC2 population (clusters 12 and 13), adjacent to pDC origin, distinct from the origin of DC3 in CD34^int^SIRPA^+^ pre-DC3 (clusters 10, 14, and 15), close to monocyte origin. IRF8 transcription and protein expression were higher in the DC2 trajectory than in DC3 ([Figures 4](#fig4){ref-type="fig"}J and 4K). As expected, IRF8 protein was low in both mature DC2s and DC3s ([Figure 4](#fig4){ref-type="fig"}L).

PB CD123^int^ precursors were similar to those isolated from BM with respect to scRNA-seq profiles and *in vitro* culture potential. IRF8^hi^CD123^+^CD2^+^AXL^+^CD5^+^ precursors, previously described as pre-DC (See) and AS DC (Villani), generated only DC2s ([Figures S4](#mmc1){ref-type="supplementary-material"}L--S4R).

Differential IRF8 Expression Defines the Two Pathways of DC Development {#sec2.5}
-----------------------------------------------------------------------

Having identified the trajectories and key antigens mapping DC differentiation in BM and PB, we sought to integrate progenitors, precursors, and mature cells using an independent method. We used a CyTOF panel including progenitor markers (CD34 and CD117), intracellular TFs (IRF4 and IRF8), early DC lineage markers (AXL, SIGLEC6, CD123, CD2, CD33, and SIRPA), and mature DC and monocyte antigens ([Figures 5](#fig5){ref-type="fig"}A--5F and [S5](#mmc1){ref-type="supplementary-material"}A--S5E; [Table S2](#mmc1){ref-type="supplementary-material"}) to simultaneously analyze cells from BM and PB. Using tSNE dimension reduction, PB cells containing pDCs, cDC1s, CD1c^+^ DCs, and classical and nonclassical monocytes were located peripherally to progenitors and precursors present in BM. Populations were identified by key antigen expression or back-gating of sequentially gated populations ([Figures 5](#fig5){ref-type="fig"}A, 5B, [S5](#mmc1){ref-type="supplementary-material"}B, and S5C). As previously shown, CD1c^+^ DCs, including the DC3 portion, were distinct from classical monocytes.Figure 5Differential IRF8 Expression Defines the Two Trajectories of DC Development(A--E) CyTOF analysis of FACS-purified CD45^+^lin(CD3,19,20,56,161)^−^ PB and BM progenitors, precursors, and mature DCs and monocytes using a panel of 33 surface antigens and two intracellular stains (IRF4 and IRF8). (A) tSNE visualization of lin^−^HLA-DR^+^ cells, down-sampled to select 75,000 cells (20,000 CD11b^+^CD14^+^ monocytes, 4,000 CD11b^+^CD16^+^ monocytes, and 50,000 non-monocyte cells). PB (red) and BM (gray) cells were distinguished by differential CD45^+^ conjugate staining and displayed across tSNE space. (B) Heatmap of DC or monocyte-subset-specific antigens displayed on tSNE plots as in (A) (blue-yellow-red scales represent channel values). "Mature cells" plot shows the location of DC and monocyte subsets and CD34^+^ progenitors, identified by back-gating from bivariate plots ([Figures S5](#mmc1){ref-type="supplementary-material"}B--S5D). (C) The location in tSNE space of IRF8^hi^ (red) and IRF8^lo^ (orange) expressing cells identified by (1) standard gating on a bivariate plot of IRF8 versus CD304 and superimposition of these gated cells on tSNE space and (2) a heatmap of IRF8 expression across all cells. (D and E) Location in tSNE space of progenitors and precursors with pDC, cDC1, or DC2 (D) and DC3 or monocyte (E) potential as defined by previous experiments, identified by back-gating from bivariate plots ([Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C), and heatmaps of associated antigens.(F) Diffusion map generated with 14,000 cells including GMPs, precursor and mature DCs, and monocytes. Populations were identified and color-coded according to [Figures 3](#fig3){ref-type="fig"}A (progenitors) and [4](#fig4){ref-type="fig"}A (precursors, DCs, and monocytes), applied to CyTOF data as shown in [Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C. Heatmaps show the expression (log2) of IRF8 and key antigens superimposed across the diffusion map trajectories. See also [Figure S5](#mmc1){ref-type="supplementary-material"}E. Diff C, diffusion component.(G) Histograms summarizing IRF8 protein expression by flow cytometry (MFI) in progenitors, precursors, and mature cells of pDC, cDC1, DC2, and DC3 lineages from BM and PB. Bars show mean ± SEM. Circles show individual donors (BM progenitors, n = 4; BM and PB precursors and mature DCs, n = 3).See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

Superimposition of IRF8^hi^ (red) and IRF8^lo^ (orange) thresholds, from a bivariate plot of IRF8 and CD304, revealed distinct nonoverlapping regions of the tSNE plot ([Figure 5](#fig5){ref-type="fig"}C). IRF8^hi^ regions contained progenitors and precursors associated with pDC, cDC1, and DC2 lineages in the preceding analyses and AXL^+^SIGLEC6^+^ (IRF8^hi^ CD123^+^) pre-DCs, present in PB and BM, connected pDCs and cDC1s with the CD5^+^ BTLA^+^ pole of CD1c^+^ DCs ([Figures 5](#fig5){ref-type="fig"}B--5D and [S5](#mmc1){ref-type="supplementary-material"}B--S5D).

In contrast, progenitors and precursors with monocyte or DC3 potential (mapped by CD117, CD33, SIRPA, and CD11c) segregated with low IRF8 expression and joined the CD1c^+^ DC cluster at a point discrete from AXL^+^SIGLEC6^+^ cells ([Figures 5](#fig5){ref-type="fig"}E, [S5](#mmc1){ref-type="supplementary-material"}B, and S5C). CD34^int^ expression was observed at both IRF8^hi^ and IRF8^lo^ contact points with the CD1c^+^ DC population ([Figure 5](#fig5){ref-type="fig"}B). As previously demonstrated ([Figures 2](#fig2){ref-type="fig"}C and [4](#fig4){ref-type="fig"}L), IRF8 was not expressed in mature CD1c^+^ DCs.

Diffusion mapping of 14,000 randomly sampled GMP, precursor, and mature populations from the experiment produced a result coherent with the preceding *in vitro* culture outputs and with trajectories driven by scRNA-seq data ([Figure 5](#fig5){ref-type="fig"}F; [Data S3](#mmc4){ref-type="supplementary-material"}). The analysis generated a tetrahedron in Euclidean space with progenitors at the apex and monocytes, pDCs, and cDC1s at the vertices. DC3 and DC3 precursors lay close to the monocyte pathway linked to the GMP33^+^ by IRF8^lo^ populations (brown and rust). DC2 precursors descended closer to pDCs through CD123^lo-int^ IRF8^hi^ GMPs (lilac). As expected, mature DC2s and DC3s lay between monocytes and DCs along diffusion component 1. Both mature populations expressed FCER1, SIRPA, and CD2, but there was mutually exclusive expression of CD14 and CD5. These pathways could be visualized on standard bivariate plots ([Figures S5](#mmc1){ref-type="supplementary-material"}F and S5G). Intracellular flow was used to pinpoint the stage-specific expression of IRF8 protein along each pathway of DC development ([Figure 5](#fig5){ref-type="fig"}G).

IRF8^hi^ and IRF8^lo^ Pathways Are Differentially Compromised in IRF8 Deficiency {#sec2.6}
--------------------------------------------------------------------------------

We analyzed nine individuals from three kindreds with *IRF8* mutation to define the dependence of each pathway of DC development on IRF8 activity. Bi-allelic *IRF8*^*K108E/K108E*^ and *IRF8*^*R83C/R291Q*^ patients were compared with their minimally affected heterozygous parents ([@bib20]; [@bib6]) and three individuals from a third kindred with an autosomal-dominant phenotype due to dominant-negative *IRF8*^*V426fs*^ (unpublished data).

Heterozygous parents of the child carrying *IRF8*^*R83C/R291Q*^ had 20%--50% loss of pDCs, cDC1s, and CD1c^+^ DCs ([Figures 6](#fig6){ref-type="fig"}A and 6B). In retrospect this matched the phenotype of heterozygous *IRF8*^*K108E*^ ([@bib20]) and is in keeping with a gene-dosage effect of *IRF8* on DC development. *IRF8*^*V426fs*^ mutation produced an intermediate cellular phenotype congruent with clinical manifestations that were more severe than heterozygotes (*IRF8*^*R83C*^ and *IRF8*^*R291Q*^) but less than bi-allelic *IRF8* deficiency (*IRF8*^*R83C/R291Q*^) ([Figures 6](#fig6){ref-type="fig"}A, 6B, and [S6](#mmc1){ref-type="supplementary-material"}A). Both pDCs and cDC1s were depleted with *V426fs* mutation. A trend toward monocytosis in the asymptomatic heterozygotes (*IRF8*^*R83C*^ and *IRF8*^*R291Q*^) became significant in *IRF8*^*V426fs*^.Figure 6IRF8^hi^ and IRF8^lo^ Pathways Are Differentially Compromised in IRF8 Deficiency(A) PB flow analysis of monocytes and DCs in subjects carrying heterozygous *IRF8*^*R83C*^ or *IRF8*^*R291Q*^ mutation (Het), their child carrying *IRF8*^*R83C/R291Q*^ (Bi), and a carrier of dominant-negative heterozygous mutation *IRF8*^*V426fs*^ (Dom) compared with HC (Cont).(B) Trucount quantification of PB DCs and monocytes in subjects carrying *IRF8* mutations (gating shown in [Figure S6](#mmc1){ref-type="supplementary-material"}A; [@bib20]; [@bib6])). Cont, n = 25; Het, n = 4 (*IRF8*^*R83C*^, *IRF8*^*R291Q*^, and two subjects carrying *IRF8*^*K108E*^); Dom, n = 3 (*IRF8*^*V426fs*^); Bi, n = 2 (*IRF8*^*R83C/R291Q*^ and *IRF8*^*K108E/K108E*^).(C) Flow cytometry phenotyping of CD1c^+^ DC subsets derived from the CD1c^+^CD2^+^ gate (gray) in (A) to identify CD14^+^ DC3s (orange), CD14^−^BTLA^−^ DC3s (light orange), CD5^−^BTLA^+^ DC2s (light red), and CD5^+^BTLA^+^ DC2s (red).(D) Proportion of CD1c^+^ DC subsets (gated as in C, from the individuals represented in B). C, control; H, heterozygous parents; D, dominant-negative heterozygotes (*IRF8*^*V426fs*^).(E) Flow analysis of DC and monocyte precursors in PB of subjects carrying *IRF8* mutations as shown, gated as in [Figure 4](#fig4){ref-type="fig"}C.(F) Proportion of DC and monocyte precursors out of all pre-DCs in PB of subjects carrying *IRF8* mutations, gated as in (E). C, control; H, heterozygous; D, *IRF8*^*V426fs*^(G and H) Intracellular flow analysis of *in vitro* cytokine elaboration (percentage of positive cells) by CD14^+^ monocytes (black), CD14^+^ DC3s (orange), CD14^−^CD5^−^CD1c^+^ DCs (gray), and CD5^+^ DC2s (red) (G) and CD2^+^ pre-pDCs and pDCs from HC (n = 8) and subjects carrying heterozygous *IRF8*^*R83C*^, IRF8^R291Q^ (mean of technical duplicates) or IRF8^V426fs^ (IRF8, red-outlined bars) (H). See also [STAR Methods](#sec4){ref-type="sec"} and [Figure 1](#fig1){ref-type="fig"}H.Bars show mean ± SEM, and circles represent individual subjects. ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001; ˆp = 0.053, Mann-Whitney U. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

CD1c^+^ DCs presented a paradox; although *IRF8*^*R83C*^ and *IRF8*^*R291Q*^ were lower than controls, lower IRF8 activity in *IRF8*^*V426fs*^ restored CD1c^+^ DCs ([Figure 6](#fig6){ref-type="fig"}C). The proportion of DC2s and DC3s accounted for this anomaly; DC2s, pDCs, and cDC1s decreased with loss of IRF8, but this was compensated for by an increase in DC3 such that CD1c^+^ DC population of *IRF8*^*V426fs*^ consisted almost entirely of DC3s ([Figure 6](#fig6){ref-type="fig"}D). Parallel effects occurred in pre-DCs as defined by the preceding analysis; AXL^+^CD5^+^ pre-DC2s were lost in parallel with DC2s, but SIRPA/B^+^CD2^+^ pre-DC3s increased proportionately with DC3s and monocytes ([Figures 6](#fig6){ref-type="fig"}E and 6F). In heterozygotes with sufficient cells to analyze, loss of IRF8 reduced tumor necrosis factor (TNF) and IL-12 in DC2s and DC3s while IFN-α and TNF production was decreased in CD2^+^pre-pDCs and pDCs ([Figures 6](#fig6){ref-type="fig"}G, 6H, [S6](#mmc1){ref-type="supplementary-material"}B, and S6C).

IRF8 Deficiency Causes Dose-Dependent Blockade of the IRF8^hi^ Pathway {#sec2.7}
----------------------------------------------------------------------

Seeking further evidence of a dissociation between IRF8^hi^ and IRF8^lo^ DC pathways, we probed the progenitor and DC precursor compartments of BM for dose-dependent effects of *IRF8*^*V426fs*^ and *IRF8*^*R83C/R291Q*^ ([Figures 7](#fig7){ref-type="fig"}A, 7B, and [S7](#mmc1){ref-type="supplementary-material"}A). We inferred the point of developmental blockade by expansion of a proximal population coupled with loss of cells immediately distal to it (red arrows, [Figure 7](#fig7){ref-type="fig"}C). In the IRF8^hi^ pathway, defects occurred increasingly more proximally; heterozygous mutations affected the precursors, and dominant-negative and bi-allelic mutations impacted the proportions of CD123^lo^, CD123^int^, and CD33^−^CD117^−^ GMPs in a stepwise fashion. In contrast, the IRF8^lo^ pathway leading to DC3s was only sensitive to complete bi-allelic loss of *IRF8,* late in the precursor compartment.Figure 7IRF8 Deficiency Causes Dose-Dependent Blockade of the IRF8^hi^ Pathway(A and B) Flow cytometry analysis of BM CD34^+^ progenitors (A) and DC and monocyte precursors (B) from the subjects carrying dominant-negative *IRF8*^*V426f*s^ and bi-allelic *IRF8* mutations and an age-matched control (AM Cont). BM was not available from healthy heterozygotes *IRF8*^*R83C*^ and *IRF8*^*R291Q*^. Gating and color coding as in [Figures 3](#fig3){ref-type="fig"}A and [4](#fig4){ref-type="fig"}C.(C) The relative proportions of progenitors and precursors in BM and PB from controls (n = 3 BM, n = 4 PB) and individuals carrying heterozygous *IRF8*^*R83C*^ and *IRF8*^*R291Q*^ (PB, Het), *IRF8*^*V426f*s^ (Dom), or *IRF8*^*R83C/R291Q*^*(Bi)* to pinpoint the block associated with progressive loss of IRF8 activity for each DC lineage. CD34^+^ populations were expressed as a proportion of total gated CD34^+^ cells. Precursor and mature DC populations were expressed as a proportion of the total number of gated CD34^neg-int^ cells. Likely points of blockade are indicated by red arrows.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

*In vitro* differentiation and transcriptomic analyses provided evidence of two pathways of DC development, distinguished by their high or low IRF8 expression, giving rise to cDC1s, pDCs, and DC2s or DC3s and monocytes, respectively.

In partial IRF8 deficiency, the incremental loss of subsets derived from the IRF8^hi^ trajectory, associated with preservation or expansion of IRF8^lo^ populations, demonstrates the differential IRF8 requirement of these pathways in the intact human.

Discussion {#sec3}
==========

CD1c^+^ DCs are heterogeneous by phenotype, gene expression, and function. DC2s are enriched for classical cDC1-related properties, while DC3s are closer to monocytes ([@bib46]; [@bib56]; [@bib2]; [@bib25]; [@bib54]; [@bib57]). Here, we have shown that this heterogeneity originated in two distinct pathways of hematopoiesis, with differential requirements for IRF8. Using *in vitro* differentiation assays tuned to distinguish between DC2 and DC3 outputs, we showed that their developmental potentials lie in mutually exclusive populations of progenitors and precursors. Two developmental trajectories were apparent from high-dimensional analysis of antigen expression, unbiased scRNA-seq, and diffusion mapping. Finally, a human *IRF8* allelic series revealed differential sensitivity of the two pathways to loss of IRF8 activity.

The DC2 IRF8^hi^ pathway followed a classical DC trajectory closely related to pDCs and cDC1s. Distinct DC2 potential was first evident in LMPPs, which were heterogeneous at single-cell resolution, and was traceable through CD123^lo^CD33^−^CD117^−^ GMPs. Progressive enrichment of IRF8^hi^ pathway DC potential was observed with increasing CD123 expression in the GMP compartment. The maximum expression of CD123 by GMPs was CD123^int^ relative to CD123^hi^ expression in PB. The CD123^+^ tip of the GMP generated the CD123^hi^ cells found among CD34^int^ BM and PB cells, containing restricted pDC and DC2 potential. CD5 and transient expression of AXL and SIGLEC6 separated these two components. As CD123 expression was lost, the characteristic CD1c^+^ DC markers CD11c and CD1c were progressively acquired, IRF8 was downregulated, and IRF4 dominance was acquired. pDCs developed along a CD123^hi^ trajectory marked by continued high expression of IRF8 and IRF4, acquiring CD303/4 as CD34 expression was lost. The cDC1 trajectory, characterized by the highest IRF8 expression, took a variant route from the GMP. The most enriched flux appeared to leave the CD123^int^ tip of the GMP as a small population of cells retaining residual proliferative capacity and CD34^int^ expression. These became CD123^int^CD11c^lo^ PB cells that subsequently acquired CD141, CLEC9A, and a state of high IRF8 unopposed by IRF4. This population was previously detected among multiply lineage-negative cells by co-expression of CD100 and CD34 but not connected to the cDC1 trajectory ([@bib54]). Pre-DC2s and pre-cDC1s were much more obvious when lin^−^HLA-DR^+^ BM cells were fractionated by decrements of CD34 expression.

The DC3 pathway was related to monocyte development, marked by low expression of IRF8. However, DC3s are not "monocyte derived" for the following reasons: (1) they were observed fully formed in the BM compartment, (2) their potential was highest in a phenotypically defined precursor group independent of monocytes (SIRPA/B^+^CD2^+^), (3) they appeared in progenitor cell culture earlier than monocytes, and (4) they developed under conditions that prevent monocyte differentiation into DC3.

Enrichment for DC2 and DC3 potential within discrete progenitor populations is congruent with lineage-primed descriptions of hematopoiesis, in which DC potential is specified at an early stage ([@bib45]; [@bib29]). Specifically, we observed DC2 trajectory transcriptomes in subsets of LMPP and CD123^neg-lo^CD33^−^ GMP and DC3 and monocyte-related transcriptomes, distinct from granulocyte precursors, in the CD123^neg-lo^CD33^+^ GMP.

The developmental trajectories of pDCs, cDC1s, and CD1c^+^ DCs (DC2 and DC3 together) have been previously mapped at single-cell resolution by [@bib29], who demonstrated that the CD123^int^ GMP contains only unipotent cell potential (pDCs, cDC1s, or CD1c^+^ DCs) and that the CD123^neg-lo^ GMP contains cells with dual cDC1 and CD1c^+^ DC or CD1c^+^ DC and mono- potential. Herein, we have shown that the cDC1 and CD1c^+^DC potential of CD123^lo-int^GMP gave rise almost exclusively to DC2 while the greatest enrichment of monocyte and DC3 potential was found in the CD123^neg-lo^CD33^+^ subset of GMP. The use of single cultures would not alter the interpretation of our data that the outputs of these two GMP fractions are distinct. Where single-cell cultures will be essential, in future experiments, is to explore lineage-priming at the origin of the DC2 and DC3 pathways in primitive HSC or MPP populations. It also remains to be determined whether alternative exogenous factors can modulate the potentials demonstrated *in vitro*.

Many reports have highlighted dose-dependent effects of *Irf8* on murine DC development ([@bib51]; [@bib16]; [@bib48]). Collectively, these show that cDC1s are most sensitive to Irf8 loss, requiring high expression at the terminal stages of differentiation. Murine pDCs survive Irf8 deficiency but are functionally altered, while the equivalents of CD1c^+^ DCs (cDC2s) are preserved. Monocytes are not affected until *Irf8* is ablated, when they are blocked at the GMP stage.

In humans, reduced IRF8 activity in asymptomatic heterozygotes and individuals with the dominant-negative *V426fs* allele was associated with reduction or depletion of all of the IRF8^hi^ pathway classical DCs (pDCs, cDC1s, and DC2s). In contrast, IRF8^lo^ DC3s and monocytes were maintained or even expanded until IRF8 activity was completely absent in the patients carrying bi-allelic mutations, resulting in the loss of all DCs and monocytes. In contrast to mouse, human pDCs were almost as sensitive as cDC1s to loss of IRF8. However, in asymptomatic heterozygotes, where there was only partial depletion, we observed an increased proportion of CD2^+^ pDCs and functional deficits in IFN-α and TNF production similar to that reported in mice ([@bib48]). When CD1c^+^DCs are considered as a single entity, the total population appeared to remain intact in the context of partial depletion of IRF8, as observed in asymptomatic heterozygotes and individuals with the dominant-negative *V426fs* allele. However, separation of CD1c^+^ DCs into IRF8^hi^ pathway DC2 and IRF8^lo^ pathway DC3 components showed that DC3s populated the parameter space left empty by missing DC2s. A dominant-negative allele of *IRF8* has been previously reported with the substitution *T80A* ([@bib20]). Although this was originally thought to have intact cDC1s and a defect of CD1c^+^ DCs, improved analysis using CLEC9A recently confirmed that cDC1s are indeed selectively depleted in these heterozygous individuals ([@bib24]). Lower expression of CD1c is also possibly explained by replacement of DC2 by DC3. Thus, all *IRF8*-mutated individuals now show congruous cellular phenotypes.

These observations highlight the phenomenon that cellular deficiency due to hematopoietic TF mutation often results in expansion of related lineages, owing to the unopposed action of competing TFs. We have previously described the marked neutrophilia accompanying bi-allelic *IRF8* deficiency ([@bib20]; [@bib6]), probably due to the action of unopposed CEBPα ([@bib5]; [@bib26]). In this study, we have reported monocytosis and expansion of DC3 in *IRF8* heterozygous states potentially related to excessive SPI1 (PU.1) activity when IRF8 is partially absent ([@bib29]; [@bib15]).

Our results reinforce the view that gene-dosage effects and autosomal-dominant patterns of inheritance often occur in TFs controlled by super-enhancers ([@bib1]). Experimentally, this proved critical in analyzing the differential requirement for IRF8 between two DC pathways. Through this analysis, we have refined the concept of "classical DCs" as cDC1 and DC2 dependent on the IRF8^hi^ pathway and distinct from DC3 and monocyte development by the IRF8^lo^ pathway. Although we do not have a biochemical means of assessing total IRF8 "activity" in the intact hematopoietic system and made inferences from the severity of clinical phenotypes, all the mutations described are deleterious in reporter assays ([@bib6]).

In conclusion, our data support a model whereby CD1c^+^ DC heterogeneity arises from distinct lineage trajectories within the CD34^+^ progenitor compartment, progressing along pathways distinguished by high or low IRF8 expression, comprised of phenotypically identifiable precursors. Distal convergence to a CD1c^+^ DC phenotype results in the observed phenotypic, transcriptomic, and functional heterogeneity of CD1c^+^ DCs.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Mouse anti-APC 176Yb, clone APC003FluidigmCat\# 3176007BMouse anti-human AXL APC, clone 108724R&D SystemsCat\# FAB154AMouse anti-human AXL purified, clone 108724R&D SystemsCat\# MAB154; RRID:[AB_2062558](nif-antibody:AB_2062558){#intref0010}Mouse anti-human BTLA 163Dy, clone MIH26FluidigmCat\# 3163009BMouse anti-human BTLA BV650, clone J168-540BD BiosciencesCat\# 564803; RRID:[AB_2738962](nif-antibody:AB_2738962){#intref0015}Mouse anti-human CD1c APC-Cy7, clone L161BioLegendCat\# 331520; RRID:[AB_10644008](nif-antibody:AB_10644008){#intref0020}Mouse anti-human CD1c PE-Cy7, clone L161BioLegendCat\# 331516; RRID:[AB_2275574](nif-antibody:AB_2275574){#intref0025}Mouse anti-human CD1c PerCP-Cy5.5, clone L161BioLegendCat\# 331513; RRID:[AB_1227536](nif-antibody:AB_1227536){#intref0030}Mouse anti-human CD1c purified, clone L161BioLegendCat\# 331502; RRID:[AB_1088995](nif-antibody:AB_1088995){#intref0035}Mouse anti-human CD2 151Eu, clone TS1/8FluidigmCat\# 3151003BMouse anti-human CD2 BV421, clone TS1/8BioLegendCat\# 309217; RRID:[AB_10915139](nif-antibody:AB_10915139){#intref0040}Mouse anti-human CD2 PE-CF594, clone RPA-2.10BD BiosciencesCat\# 562300; RRID:[AB_11153492](nif-antibody:AB_11153492){#intref0045}Mouse anti-human CD3 AF700, clone SK7 (Leu-4)BioLegendCat\# 344822; RRID:[AB_2563420](nif-antibody:AB_2563420){#intref0050}Mouse anti-human CD3 FITC, clone SK7(Leu-4)BD BiosciencesCat\# 345763Mouse anti-human CD3 PE, clone SK7(Leu9)BD BiosciencesCat\# 345765Mouse anti-human CD5 BUV737, clone UCHT2BD BiosciencesCat\# 564451; RRID:[AB_2714177](nif-antibody:AB_2714177){#intref0055}Mouse anti-human CD5 purified, clone L17F12BioLegendCat\# 364002; RRID:[AB_2564477](nif-antibody:AB_2564477){#intref0060}Mouse anti-human CD7 FITC, clone Leu-9BD BiosciencesCat\# 347483; RRID:[AB_400309](nif-antibody:AB_400309){#intref0065}Mouse anti-human CD7 PE, clone M-T701BD BiosciencesCat\# 332774Mouse anti-human CD10 156Gd, clone HI10aFluidigmCat\# 3156001BMouse anti-human CD10 BV650, clone HI10aBD BiosciencesCat\# 563734; RRID:[AB_2738393](nif-antibody:AB_2738393){#intref0070}Mouse anti-human CD11b 144Nd, clone ICRF44FluidigmCat\# 3144001BMouse anti-human CD11c 159Tb, clone Bu15FluidigmCat\# 3159001BMouse anti-human CD11c AF700, clone B-ly6BD BiosciencesCat\# 561352; RRID:[AB_10612006](nif-antibody:AB_10612006){#intref0075}Mouse anti-human CD11c APC-Cy7, clone Bu15BioLegendCat\# 337218; RRID:[AB_10662746](nif-antibody:AB_10662746){#intref0080}Mouse anti-human CD11c BV711, clone B-ly6BioLegendCat\# 301630; RRID:[AB_2562192](nif-antibody:AB_2562192){#intref0085}Mouse anti-human CD14 BV650, clone M5E2BioLegendCat\# 301835; RRID:[AB_11204241](nif-antibody:AB_11204241){#intref0090}Mouse anti-human CD14 FITC, clone M5E2BD BiosciencesCat\# 555397; RRID:[AB_395798](nif-antibody:AB_395798){#intref0095}Mouse anti-human CD14 PE, clone M5E2BD BiosciencesCat\# 555398; RRID:[AB_395799](nif-antibody:AB_395799){#intref0100}Mouse anti-human CD14 PE-Cy7, clone HCD14BioLegendCat\# 325618; RRID:[AB_830691](nif-antibody:AB_830691){#intref0105}Mouse anti-human CD14 purified, clone M5E2BioLegendCat\# 301802; RRID:[AB_314184](nif-antibody:AB_314184){#intref0110}Mouse anti-human CD15 164Dy, clone W6D3FluidigmCat\# 3164001BMouse anti-human CD15 BUV395, clone HI98BD BiosciencesCat\# 563872; RRID:[AB_2738461](nif-antibody:AB_2738461){#intref0115}Mouse anti-human CD15 BV605, clone W6D3BD BiosciencesCat\# 562979; RRID:[AB_2744292](nif-antibody:AB_2744292){#intref0120}Mouse anti-human CD16 209Bi, clone 3G8FluidigmCat\# 3209002BMouse anti-human CD16 AF700, clone 3G8BioLegendCat\# 302026; RRID:[AB_2278418](nif-antibody:AB_2278418){#intref0125}Mouse anti-human CD16 FITC, clone 3G8BD BiosciencesCat\# 335035Mouse anti-human CD16 PE, clone 3G8BD BiosciencesCat\# 555407; RRID:[AB_395807](nif-antibody:AB_395807){#intref0130}Mouse anti-human CD16 PE-Dazzle594, clone 3G8BioLegendCat\# 302054; RRID:[AB_2563639](nif-antibody:AB_2563639){#intref0135}Mouse anti-human CD19 AF700, clone 4G7/HIB19BioLegendCat\# 302226; RRID:[AB_493751](nif-antibody:AB_493751){#intref0140}Mouse anti-human CD19 FITC, clone 4G7BD BiosciencesCat\# 345776Mouse anti-human CD19 PE, clone HIB19BD BiosciencesCat\# 555413; RRID:[AB_395813](nif-antibody:AB_395813){#intref0145}Mouse anti-human CD20 AF700, clone L27/2H7BioLegendCat\# 302322; RRID:[AB_493753](nif-antibody:AB_493753){#intref0150}Mouse anti-human CD20 FITC, clone L27BD BiosciencesCat\# 345792Mouse anti-human CD20 PE, clone L27BD BiosciencesCat\# 345793Mouse anti-human CD33 158Gd, clone WM53FluidigmCat\# 3158001BMouse anti-human CD33 APC, clone P67.6BD BiosciencesCat\# 345800Mouse anti-human CD33 BV711, clone WM53BD BiosciencesCat\# 563171; RRID:[AB_2738045](nif-antibody:AB_2738045){#intref0155}Mouse anti-human CD34 166Er, clone 581FluidigmCat\# 3166012BMouse anti-human CD34 APC-Cy7, clone 581BioLegendCat\# 343514; RRID:[AB_1877168](nif-antibody:AB_1877168){#intref0160}Mouse anti-human CD34 BV605, clone 581BioLegendCat\# 343529; RRID:[AB_2562193](nif-antibody:AB_2562193){#intref0165}Mouse anti-human CD34 FITC, clone 8G12BD BiosciencesCat\# 345801Mouse anti-human CD34 PE-CF594, clone 581BD BiosciencesCat\# 562383; RRID:[AB_11154586](nif-antibody:AB_11154586){#intref0170}Mouse anti-human CD36 155Gd, clone 5-271FluidigmCat\# 3155012BMouse anti-human CD38 PE-Cy7, clone HB7BD BiosciencesCat\# 335825Mouse anti-human CD38 purified, clone HB-7BioLegendCat\# 356602; RRID:[AB_2561794](nif-antibody:AB_2561794){#intref0175}Mouse anti-human CD45 89Y, clone HI30FluidigmCat\# 3089003BMouse anti-human CD45 APC-Cy7, clone 2D1BD BiosciencesCat\# 557833; RRID:[AB_396891](nif-antibody:AB_396891){#intref0180}Mouse anti-human CD45 V450, clone 2D1BD BiosciencesCat\# 642275; RRID:[AB_1645755](nif-antibody:AB_1645755){#intref0185}Mouse anti-human CD45RA 153Eu, clone HI100FluidigmCat\# 3153001BMouse anti-human CD45RA BV510, clone HI100BioLegendCat\# 304142; RRID:[AB_2561947](nif-antibody:AB_2561947){#intref0190}Rat anti-human CD52 PE, clone YTH34.5Bio-RadCat\# SFL1642PE; RRID:[AB_324131](nif-antibody:AB_324131){#intref0195}Mouse anti-human CD56 FITC, clone NCAM16.2BD BiosciencesCat\# 345811Mouse anti-human CD88 PE, clone S5/1BioLegendCat\# 344304; RRID:[AB_2067175](nif-antibody:AB_2067175){#intref0200}Mouse anti-human CD88 purified, clone C5ARBioLegendCat\# 344302; RRID:[AB_2259318](nif-antibody:AB_2259318){#intref0205}Mouse anti-human CD90 161Dy, clone 5E10FluidigmCat\# 3161009Mouse anti-human CD90 AF700, clone 5E10BioLegendCat\# 328120; RRID:[AB_2203302](nif-antibody:AB_2203302){#intref0210}Mouse anti-human CD90 PerCP-Cy5.5, clone 5E10BioLegendCat\# 328118; RRID:[AB_2303335](nif-antibody:AB_2303335){#intref0215}Human anti-human CD100 APC-Vio770, clone REA316Miltenyi BiotecCat\# 130-104-604; RRID:[AB_2654328](nif-antibody:AB_2654328){#intref0220}Mouse anti-human CD100 purified, clone A8BioLegendCat\# 328401; RRID:[AB_1236386](nif-antibody:AB_1236386){#intref0225}Mouse anti-human CD115 purified, clone 9-4D2-1E4BioLegendCat\# 347302; RRID:[AB_2085375](nif-antibody:AB_2085375){#intref0230}Mouse anti-human CD116 BV421, clone hGMCSFR-M1BD BiosciencesCat\# 564045; RRID:[AB_2738561](nif-antibody:AB_2738561){#intref0235}Mouse anti-human CD116 BV650, clone hGMCSFR-M1BD BiosciencesCat\# 564044; RRID:[AB_2738560](nif-antibody:AB_2738560){#intref0240}Mouse anti-human CD116 purified, clone 4H1BioLegendCat\# 305902; RRID:[AB_314568](nif-antibody:AB_314568){#intref0245}Mouse anti-human CD117 BV605, clone 104D2BD BiosciencesCat\# 562687; RRID:[AB_2737721](nif-antibody:AB_2737721){#intref0250}Mouse anti-human CD117 PE, clone 104D2BD BiosciencesCat\# 332785Mouse anti-human CD117 purified, clone 104D2BioLegendCat\# 313201; RRID:[AB_314980](nif-antibody:AB_314980){#intref0255}Mouse anti-human CD123 143Nd, clone 6H6FluidigmCat\# 3143014BMouse anti-human CD123 BUV395, clone 7G3BD BiosciencesCat\# 564195; RRID:[AB_2714171](nif-antibody:AB_2714171){#intref0260}Mouse anti-human CD123 BV421, clone 6H6BioLegendCat\# 306018; RRID:[AB_10962571](nif-antibody:AB_10962571){#intref0265}Mouse anti-human CD123 PerCP-Cy5.5, clone 7G3BD BiosciencesCat\# 558714; RRID:[AB_1645547](nif-antibody:AB_1645547){#intref0270}Mouse anti-human CD135 BV711, clone 4G8BD BiosciencesCat\# 563908; RRID:[AB_2738479](nif-antibody:AB_2738479){#intref0275}Mouse anti-human CD135 purified, clone BV10A4H2BioLegendCat\# 313302; RRID:[AB_314987](nif-antibody:AB_314987){#intref0280}Mouse anti-human CD141 BV510, clone 1A4BD BiosciencesCat\# 563298; RRID:[AB_2728103](nif-antibody:AB_2728103){#intref0285}Mouse anti-human CD141 purified, clone M80BioLegendCat\# 344102; RRID:[AB_2201808](nif-antibody:AB_2201808){#intref0290}Mouse anti-human CD161 PE-Cy7, clone HP-3G10Thermo Fisher ScientificCat\# 25-1619-42; RRID:[AB_10807086](nif-antibody:AB_10807086){#intref0295}Mouse anti-human CD303 147Sm, clone 201AFluidigmCat\# 3147009BMouse anti-human CD303 APC, clone 201ABioLegendCat\# 354206; RRID:[AB_11150412](nif-antibody:AB_11150412){#intref0300}Mouse anti-human CD303 BV605, clone 201ABioLegendCat\# 354224; RRID:[AB_2572149](nif-antibody:AB_2572149){#intref0305}Mouse anti-human CD304 169Tm, clone 12C2FluidigmCat\# 3169018BMouse anti-human CD304 APC, clone 12C2BioLegendCat\# 354506; RRID:[AB_11219600](nif-antibody:AB_11219600){#intref0310}Mouse anti-human CD304 BV605, clone U21-1283BD BiosciencesCat\# 743130; RRID:[AB_2741297](nif-antibody:AB_2741297){#intref0315}Mouse anti-human CLEC9A PE, clone 8F9BioLegendCat\# 353804; RRID:[AB_10965546](nif-antibody:AB_10965546){#intref0320}Mouse anti-human CLEC9A purified, clone 8F9BioLegendCat\# 353802; RRID:[AB_10983070](nif-antibody:AB_10983070){#intref0325}Rat anti-human CX3CR1 APC, clone 2A9-1BioLegendCat\# 341610; RRID:[AB_2087424](nif-antibody:AB_2087424){#intref0330}Mouse anti-human FceRI 150Nd, clone AER-37 (CRA-1)FluidigmCat\# 3150027BMouse anti-FITC purified, clone FIT-22BioLegendCat\# 408305; RRID:[AB_2563769](nif-antibody:AB_2563769){#intref0335}Mouse anti-human HLA-DR 173Yb, clone L243FluidigmCat\# 3173005BMouse anti-human HLA-DR AF700, clone G46-6BD BiosciencesCat\# 560743; RRID:[AB_1727526](nif-antibody:AB_1727526){#intref0340}Mouse anti-human HLA-DR BV785, clone L243BioLegendCat\# 307642; RRID:[AB_2563461](nif-antibody:AB_2563461){#intref0345}Mouse anti-human HLA-DR PerCP-Cy5.5, clone L243BioLegendCat\# 307629; RRID:[AB_893575](nif-antibody:AB_893575){#intref0350}Mouse anti-human ID2 purified, clone 4E12G5Thermo Fisher ScientificCat\# MA5-17095; RRID:[AB_2538566](nif-antibody:AB_2538566){#intref0355}Mouse anti-human IFN-a PE, clone LT27:295Miltenyi BiotecCat\# 130-092-601; RRID:[AB_871560](nif-antibody:AB_871560){#intref0360}Rat anti-human IL-10 APC, clone JES3-9D7BioLegendCat\# 501410; RRID:[AB_315176](nif-antibody:AB_315176){#intref0365}Mouse anti-human IL-12p40/p70 BV421, clone C8.6BD BiosciencesCat\# 565023; RRID:[AB_2739045](nif-antibody:AB_2739045){#intref0370}Mouse anti-human IL-1b FITC, clone JK1B-1BioLegendCat\# 508206; RRID:[AB_345362](nif-antibody:AB_345362){#intref0375}Mouse anti-human IL-8 PE-Cy7, clone E8N1BioLegendCat\# 511416; RRID:[AB_2565291](nif-antibody:AB_2565291){#intref0380}Rat anti-human IRF4 PE, clone 3E4Thermo Fisher ScientificCat\# 12-9858-80; RRID:[AB_10853179](nif-antibody:AB_10853179){#intref0385}Mouse anti-human IRF4 purified, clone IRF4.3E4BioLegendCat\# 646402; RRID:[AB_2280462](nif-antibody:AB_2280462){#intref0390}Mouse anti-human IRF8 efluor710, clone 3GYWCHThermo Fisher ScientificCat\# 46-9852-80; RRID:[AB_2573903](nif-antibody:AB_2573903){#intref0395}Mouse anti-human IRF8 purified, clone GW4CML3Thermo Fisher ScientificCat\# 14-7888-82; RRID:[AB_2572907](nif-antibody:AB_2572907){#intref0400}Goat anti-human KLF4 APC, clone POLYR&D SystemsCat\# IC3640A; RRID:[AB_2044690](nif-antibody:AB_2044690){#intref0405}Mouse anti-PE purified, clone PE001BioLegendCat\# 408105; RRID:[AB_2563787](nif-antibody:AB_2563787){#intref0410}Mouse anti-human SIGLEC-6 purified, clone 767329R&D SystemsCat\# MAB2859Mouse anti-human SIRPA purified, clone 15-414BioLegendCat\# 372102; RRID:[AB_2629807](nif-antibody:AB_2629807){#intref0415}Mouse anti-human SIRPA/B AF700, clone SE5A5BioLegendCat\# 323816; RRID:[AB_2687275](nif-antibody:AB_2687275){#intref0420}Mouse anti-human SIRPA/B APC, clone SE5A5BioLegendCat\# 323809; RRID:[AB_11219399](nif-antibody:AB_11219399){#intref0425}Mouse anti-human SIRPA/B PE, clone SE5A5BioLegendCat\# 323805; RRID:[AB_830704](nif-antibody:AB_830704){#intref0430}Mouse anti-human SLAN PE, clone DD1Miltenyi BiotecCat\# 130-093-029; RRID:[AB_871582](nif-antibody:AB_871582){#intref0435}**Biological Samples**Healthy human peripheral blood mononuclear cells (PBMC)Newcastle BiobankREC 12/NE/0395Healthy human bone marrow mononuclear cells (BMMC)Newcastle Bone and Joint Biobank and Project ethicsREC 14/NE/1212REC 13/NE/1136IRF8 patient tissuesAs previously described in [@bib20] and [@bib6]. Adult material project specific. Paediatric material through Newcastle BiobankREC 08/H0906/72REC 16/NE/0002**Chemicals, Peptides, and Recombinant Proteins**Carboxyfluorescein succinimidyl ester (CFSE, final concentration: 0.5 μM)InvitrogenCat\# C34554Lymphoprep density gradient solutionStem Cell TechnologiesCat\# 07851Dulbecco's phosphate-buffered saline (PBS)SigmaCat\# D8537-500mlFetal bovine serum, South American origin, batch 50115LabtechCat\# FCS-SA/500Ethylenediaminetetraacetic acid (EDTA)SigmaCat\# E7889DAPIPartecCat\# D8417Zombie UV Fixable Viability KitBiolegendCat\# 423108MEM Alpha Medium w/o Nucleosides (αMEM)Life TechnologiesCat\# 22561-021RPMI-1640SigmaCat\# R0883-500mlL-GlutamineSigmaCat\#G7513-100mlPenicillin-StreptomycinSigmaCat\# P0781Recombinant Human Stem Cell Factor (SCF)ImmunotoolsCat\# 11343325Recombinant human Granulocyte-Macrophage-Colony Stimulating Factor (GM-CSF)R&D systemsCat\# CAA26822Recombinant Human Flt-3 ligandImmunotoolsCat\# 11343305IgG from mouse serumSigmaCat\# I5381Triton X-100SigmaCat\# 9002-93-1Recombinant RNase inhibitor (2U/μl)Takara ClontechCat\# 2313Bpolyinosinic:polycytidylic acid (poly(I:C), final concentration: 10 μg/ml)InvivogenCat \#tlrl-picLipopolysaccharide (LPS, final concentration: 5ng/ml)SigmaCat\# L2654CL075 (final concentration: 1 μg/ml)InvivogenCat\# tlrl-c75CpG oligonucleotide (ODN 2216) (final concentration: 7.5μΜ)InvivogenCat\# tlrl-2216Brefeldin A (final concentration: 10 μg/ml)SigmaCat\# B7651-5MGFormaldehydeTAAB LaboratoriesCat\# F017/3CisplatinFluidigmCat\# 201064IrridiumFluidigmCat\# 201192AEQ Four Element Calibration BeadsFluidigmCat\# 201078**Critical Commercial Assays**Foxp3 Transcription Factor Staining Buffer SetThermo Fisher ScientificCat\# 00-5523Maxpar antibody labeling kitFluidigmN/A**Deposited Data**Single cell RNA sequencing dataHuman BM progenitorsGSE142999 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142999>Single cell RNA sequencing dataHuman BM dendritic cells and precursorsGSE143002 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143002>Single cell RNA sequencing dataHuman peripheral blood CD123+ dendritic cell precursorsGSE143158 <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143158>**Experimental Models: Cell Lines**Mouse OP9 cell lineATCCCRL-2749**Software and Algorithms**FACSDIVA 8.0.1 or 8.0 softwareBD BiosciencesN/AFlowJo 10.5.3Treestar, IncN/ACyTOF software v 6.7.1014Fluidigm<https://www.fluidigm.com/software>GraphPad Prism v5.0aGraphPad Software, Inc.N/ANanostring nSolverNanoString<https://www.nanostring.com/products/analysis-software/nsolver>**Other**LSRFortessa X20BD BiosciencesH656385K01FACS Aria Fusion SorterBD BiosciencesP656700000018Helios CyTOFFluidigmN/AGreiner CELLSTAR® 96 well platesGreinerM9436Corning® 96 Well TC-Treated Microplates size 96 wells, clear, polystyrene, round bottom, case of 50 (individually wrapped), sterile, lidCorning[CLS3799](https://www.sigmaaldrich.com/catalog/product/sigma/cls3799?lang=en&region=GB){#intref0465}50 μm sterile filterSysmex Partec04-004-2327

Resource Availability {#sec4.2}
---------------------

### Lead Contact {#sec4.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Venetia Bigley (<venetia.bigley@ncl.ac.uk>)

### Materials Availability {#sec4.2.2}

This study did not generate new unique reagents

### Data and Code Availability {#sec4.2.3}

Single cell RNA-Seq datasets generated in this study are deposited in the Genome Expression Omnibus under the following accession numbers:

Human BM progenitors [GSE142999](ncbi-geo:GSE142999){#intref0475}

(<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142999>)

Human BM dendritic cells and precursors [GSE143002](ncbi-geo:GSE143002){#intref0485}

(<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143002>)

Human PB dendritic cell precursors [GSE143158](ncbi-geo:GSE143158){#intref0495}

(<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143158>)

### Subject Details {#sec4.2.4}

The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from participants or their parents. The study was approved by local review board NRES Committee North East-Newcastle and North Tyneside: 08/H0906/72 and REC 14/NE/1136; REC 14/NE/1212, 17/NE/0361.

### Patients and healthy donors {#sec4.2.5}

Details of individuals carrying *IRF8*^K108E/K108E^ and *IRF8*^A83C/R291Q^ are previously described ([@bib20]; [@bib6]). The kindred carrying *IRF8*^V426fs^ was identified through BRIDGE whole genome sequencing initiative ([@bib38]; [@bib52]). Details and molecular characterization of the mutation will be published independently. Healthy bone marrow was obtained from hematopoietic stem cell transplant donors (pediatric or adult) or from hip arthroplasty (adult).

Method Details {#sec4.3}
--------------

### Flow cytometry and cell sorting {#sec4.3.1}

Healthy control mononuclear cells from peripheral blood (PBMC) or bone marrow (BMMC), isolated by density centrifugation, were stained in aliquots of 3 x10^6^ cells/50 μL of Dulbecco's phosphate-buffered saline (PBS) with 0.1%--2% fetal calf serum (FCS, GIBCO) and 0.4% EDTA for 30min at room temperature (RT). Non-specific staining was blocked with 3 μL mouse IgG prior to staining. Dead cells, usually \< 5%, were excluded by DAPI (Partec) or Zombie (Biolegend) staining. Analysis was performed with a BD LSRFortessa X20 and sorting with a FACS Aria Fusion Sorter (BD Biosciences) running BD FACSDIVA 8.0.1 or 8.0 software, respectively. Purity of \> 98% was achieved in sorted populations. Data were processed with FlowJo 10.5.3 (Tree Star, Inc). Intracellular staining was performed after surface staining, lysis and fixation (eBioscience) according to manufacturer's instructions. Absolute cell counts were obtained using TruCount tubes (BD Biosciences) with 200 μL whole blood and 900 μL of red cell lysis buffer added after staining. For proliferation studies, BMMC were stained with carboxyfluorescein succinimidyl ester (CFSE, 0.5 μM, Invitrogen) prior to FACS purification according to gating strategy in [Figure 4](#fig4){ref-type="fig"}A. and cultured in standard DC differentiation conditions. CFSE dilution was assessed by flow cytometry on day 3. CD34^+^progenitors and CD14^+^monocytes were included as positive and negative controls, respectively. A full list of antibodies is provided in the [Key Resources Table](#sec4.1){ref-type="sec"}.

### *In vitro* generation of dendritic cells {#sec4.3.2}

FACS-purified human PB or BM CD34^+^ progenitors, progenitor subsets or pre-DC were cultured in 96 well U-bottomed plates (Corning) with pre-seeded OP9 stromal cells (5000vwell) in 200 μL alpha-MEM (αMEM, GIBCO) supplemented with 1% penicillin/streptomycin (Sigma), 10% FCS, 20ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF, R&D systems), 100ng/ml Flt3-ligand (FLT3, Immunotools), 20ng/ml stem cell factor (SCF, Immunotools). CD34^+^ cells were seeded at 3000/well or 500/well for serial time points. Pre-DC were seeded at 500-3000 cells/well, determined by the number of cells available after FACS-purification. Half the volume of media, with cytokines, was replaced weekly. Cells were harvested on ice at day 14 or 21; or at days 3, 5, 7, 9, 11, 14 and 21 for serial time points, passed through a 50 μm filter (Sysmex Partec), washed in PBS, and stained for flow cytometric analysis or FACS-purification.

### Dendritic cell functional analysis {#sec4.3.3}

TLR stimulation: PBMC or *in vitro* generated cells were incubated in RPMI plus 10% FCS in the presence of polyinosinic:polycytidylic acid (poly(I:C) (10 μg/ml, Invivogen), lipopolysaccharide (LPS) (5ng/ml, Sigma), CL075 (1 μg/ml, Invivogen) and CpG (7.5μΜ, Invivogen) for 14h at 37°C, 5% CO~2~ with addition of Brefaldin A (10 μg/ml, eBioscience) after 3h. Dead cells (usually \< 30%) were excluded with Zombie amine dye (Biolegend). Intracellular cytokine staining was performed after surface staining, fixation and permeabilization (eBioscience) according to manufacturer's instructions.

### NanoString nCounter analysis {#sec4.3.4}

Dendritic cell subsets and monocytes were FACS-purified (\> 98% purity) from *ex vivo* PBMC or cells generated from BM CD34^+^progenitors after 21 days in culture and lysed in RLT buffer containing 1% β-mercaptoethanol at a concentration of 2000 cells/μl. Samples were analyzed on the NanoString nCounter® platform using the Immunology V2 panel supplemented with 30 genes, as described in [@bib22].

Counts were normalized within the nSolver software (advanced analysis module version 1.1.4). The log2 transformed output data were analyzed using R v 3.3.3. For principal component analysis (PCA), genes with normalized expression values below 16 in more than half of the samples were removed (293/608 for *ex vivo* dataset and 288/608 for combined *ex vivo* and culture dataset). The remaining genes were used for the PC analyses.

A culture signature was derived by performing pairwise comparisons (two-tailed t test with Benjamini-Hochberg correction of p values) of all culture versus all *ex vivo* populations. 110 genes with adjusted p values \< 0.05 (the 'culture signature') were excluded from further analysis. The remaining 210 genes were used to construct the combined *ex vivo* and culture-derived cell PCA plot.

Statistical computation of the signature genes for the blood CD1c^+^DC subsets and monocytes was performed with Bubble GUM, a tool based on Gene Set Enrichment Analysis (GSEA) algorithm ([@bib49]). Heatmaps were generated in R and display the scaled expression of the top signature genes across the 5 blood and 3 cultured subsets. 129 signature genes with significant FDR were identified for blood monocytes (top 32 based on fold change displayed on heatmap), 32 and 16 genes for CD14^+^DC3 and CD5^+^DC2, respectively. No signature genes were identified for the CD14^-^BTLA^-^DC3 or CD5^-^BTLA^+^DC2 fractions.

### Single cell RNA sequencing {#sec4.3.5}

Single human PBMC or BMMC were index-sorted into 96-well round-bottom plates

containing 2 μL cold RNA lysis buffer (RNase-free water, 2U/μl RNase inhibitor and 0.2% Triton X-100, Sigma) (three BM progenitor plates) or SMARTer Dilution buffer (SMARTer Kit, Fluidigm) with the addition of 2U/μl RNase inhibitor (three BM precursor plates and one BM DC plate). Plates were immediately centrifugated at 500xg for 1 minute, frozen on dry ice then stored at −80oC. Each plate included 2 controls; one blank and one well containing purified mouse RNA. The reverse transcription (RT) was performed using an adapted Smart-Seq2 protocol ([@bib41]). Briefly, modifications included 21 PCR cycles and duplicate Ampure clean-up steps, following cDNA generation. The library prep was performed using the Nextera XT DNA Library Prep Kit. The Illumina HiSeq 4000 platform was employed to generate paired-end reads (75bp x 2).

### Alignment of reads to the human reference genome {#sec4.3.6}

reads were trimmed based on quality with Trimmomatic v 0.36 ([@bib7]). Bases with quality scores below Q10 (inferred base cell accuracy below 90%) were trimmed and reads shorter than 60bp were dropped. The remaining reads were aligned in the STAR mapping algorithm v 2.4.0 ([@bib13]) to the human reference genome version GRCh38.p7 (GENCODE release 25) supplemented with External RNA Controls Consortium (ERCC) spike-in controls. The files were converted from SAM format to the more compressed BAM format with SAMtools v 1.3 ([@bib30]).The count tables were obtained using HTSEQ v 0.6.1 ([@bib3]). ENSEMBL IDs were converted to HGNC gene names using biomaRt v 2.30.0 ([@bib14]).

### Gene and cell filtering {#sec4.3.7}

further analysis of the data was undertaken in R and Rstudio v 1.0.143. Quantitative details are documented in [Table S3](#mmc1){ref-type="supplementary-material"}. The Scater R package v 1.2.0 was used to perform cell and gene QC and filtering ([@bib33]). To remove technical outlier genes with poor coverage, only genes expressed at \> 2 counts in \> 2 cells were retained (range across datasets 14,458-18,791 genes). Low quality cells were removed based on number of total features, total counts, percentage of counts derived from ERCC spike-ins and % of mitochondrial gene counts (\> 20%) ([Table S3](#mmc1){ref-type="supplementary-material"}). After filtering, the number of cells remaining out of the total FACS sorted for each dataset were: BM CD34^+^ progenitors, 262/399; BM CD34^int^ pre- and mature DC, 244/260; PB pre-DC, 116/184. The normalization was performed with the RUVg method ([@bib42]) combined with counts per million (CPM) adjustment for library size and log transformation \[log2(CPM+1)\] for all downstream analyses. Only the genes annotated as protein coding in the "gene_type" column of the GENCODE reference genome GTF file were retained. To minimize the effect of cell-division cycle on the clustering performed in future steps, genes associated with cell cycle activity were downloaded from [@bib31] and removed from all our analyses. The number of protein-coding, non-cell cycle genes retained for each dataset were: BM CD34^+^ progenitors, 12406; BM CD34^int^ pre- and mature DC, 12137; PB pre-DC, 10346 ([Table S3](#mmc1){ref-type="supplementary-material"}).

### Cell clustering {#sec4.3.8}

clustering was performed with all the protein-coding, non-cell cycle genes using the Single-Cell Consensus Clustering (SC3) R package v 1.3.18 ([@bib23]). The SC3 tool requires the *k* number of number of clusters to be specified by the user. A range of clusters (2 to 15) was visualized and interrogated for each of the datasets. The output from the "sc3_estimate_k" function guided the minimum number of clusters to be considered for each of the datasets. Clustering solutions took into account cluster stability indices ('average silhouette width' \> 0.45 and 'stability index' within SC3, detailed in [Table S3](#mmc1){ref-type="supplementary-material"}), known cell phenotypes from index sorting parameters, cluster marker genes defined in previous literature and minimum number of expected populations within the dataset.

Heatmaps with marker genes were generated within SC3. The area under the receiver operating characteristic curve (AUROC) and p values assigned by a Wilcoxon signed rank test and corrected using the Holm method were used to define the marker genes (thresholds for statistics are stated in figure legends and [Table S3](#mmc1){ref-type="supplementary-material"}). Clusters were annotated based on the top statistically significant marker genes from the SC3 output, and correlated with index-sorting phenotype and culture output.

### tSNE analysis {#sec4.3.9}

the tSNE technique for dimensionality reduction was used to visualize the clusters. First, SC3 gene filter was applied to further remove genes with low expression, and those ubiquitously expressed. The remaining genes (quantified for each dataset in [Table S3](#mmc1){ref-type="supplementary-material"}) were used for tSNE analysis with the Rtsne package v 0.13. An initial PCA step was introduced to reduce dimensionality and eliminate noise. Top principal components accounting for most variance (25%--35%) were retained for the tSNE algorithm. The number of PCs is stated in the relevant figure legends).

For the BM mature DC dataset, the DC2 and DC3 signatures were downloaded from Villani et al., 2017 (90 genes) ([@bib54]). 71 of the genes were identified in our dataset and used for SC3 clustering and tSNE analysis ([Table S2](#mmc1){ref-type="supplementary-material"}), as described above.

For the signature scores displayed on tSNE embeddings or as a boxplot, the normalized counts for all genes present both in our datasets and in the DC signatures identified in Villani et al., 2017 were rescaled from 0 to 1. The average scaled signature score was then displayed on tSNE plots produced as described above. Graphics were generated with the ggplot2 package v 3.0.0.

### Diffusion maps and lineage tracing {#sec4.3.10}

diffusion maps were used to infer a pseudo-temporal ordering and reconstruct lineage branching ([@bib19]). All protein coding genes that were not known to play a role in cell cycle were used in the diffusion map calculation with the destiny tool v 2.14.0 ([@bib4]). An initial PCA step was employed to reduce noise, and PCs accounting for most variance (total of approximately 40% for both datasets) were retained for destiny. Diffusion components 1-3 were used for trajectory tracing with slingshot v 1.2.0 ([@bib50]) and visualized on 3D plots. Graphics were generated with the rgl package v 0.100.19.

### Helios Mass Cytometer (CyTOF) analysis {#sec4.3.11}

Pre-conjugated antibodies (Fluidigm), purified antibodies conjugated to their respective lanthanide metals using the Maxpar antibody labeling kit (as per manufacturer's instructions; DVS Sciences) or fluorophore-conjugated primary with anti-fluorophore metal-conjugated secondary antibodies were used for surface or intracellular staining ([Table S2](#mmc1){ref-type="supplementary-material"}; [Key Resources Table](#sec4.1){ref-type="sec"}).

Healthy control CD45^+^lineage^-^ (CD3,19,20,56,161) PBMC (3x10^6^ cells) or BMMC (1.5x 10^6^) were FACS-purified into 1ml CyTOF staining buffer (PBS plus 2% FCS). Cell staining was performed at room temperature in a final staining volume of 100ul. Centrifugation was performed at 500xg for 5 minutes unless otherwise stated. 'Barcoding' of PBMC and BMMC samples was achieved by staining with 0.5ug anti-CD45-Irr115 or anti-CD45-89Y, respectively, (30mins) in CyTOF staining buffer before washing twice in PBS. Barcoded PBMC and BMMC were combined before addition of 2.5 μM cisplatin for 5 minutes in PBS for live/dead cell discrimination, then washed promptly in CyTOF staining buffer. Successive primary and secondary surface staining was performed using approximately 0.5 μg of each antibody in CyTOF staining buffer (30mins) before washing twice with PBS. The cells were fixed in 500ml eBioscience fixation buffer (eBioscience FoxP3 fix perm kit) with the addition of 500 μL of 3.2% formaldehyde (final concentration 1.6%) and incubated for 30 minutes, before washing twice with eBioscience perm buffer. Cells were stained successively in perm buffer for 1hr each with intracellular primary and secondary antibodies then washed twice with PBS. Cells were resuspended in 500 μL 250nM Irridium in PBS (final concentration 125nM) and 500 μL 3.2% formaldehyde (final concentration 1.6%) and incubated for 1hr, before centrifugation and resuspension in 500 μL CyTOF wash buffer for overnight storage at 4°C. Prior to CyTOF acquisition, cells were washed twice in 200 μL MilliQ water (800xg for 8 minutes), counted, diluted to a maximum final concentration of 0.55x10^6^/ml in MilliQ water and filtered through a 40 μm filter (BD). EQ beads were added (10% by volume) and 1.5x10^6^ cells were acquired on the Helios mass cytometer running CyTOF software v 6.7.1014.

### tSNE analysis {#sec4.3.12}

within the CyTOF software, the resultant flow cytometry file (.fcs) was normalized against the EQ bead signals and randomized for a uniform negative distribution. FlowJo software was used to deconvolute live, lin(CD3,19,20,56)^-^HLA-DR^+^ PB or BM cells by manual gating. For individual PB and BM DC and monocyte phenotyping analyses ([Figure 1](#fig1){ref-type="fig"}G), random sampling without replacement was performed to select up to 2,300 CD141^+^Clec9A^+^ cDC1, 8,000 CD123^+^CD303^+^ pDC, 10,000 CD2^+^FCER1A^+^ CD1c^+^DC, 10,000 CD88^+^CD14^+^ monocytes and 4,000 CD88^+^CD16^+^ monocytes which were concatenated as a .fcs file and subjected to t-distributed stochastic neighbor embedding (tSNE) dimension reduction with perplexity 15 from 1000 iterations, using CD markers 36, 11b, 123, 14, 5, 1c, 11c, 2, 141, 303, 304, 88, 123 and BTLA, AXL, SIGLEC6, IRF4, IRF8, FCER1A, SIRPA. Heat plots of marker expression (ArcSinh scale, with cofactor of 5) on the reduced dimensions were generated within FlowJo.

For combined PB and BM progenitor, pre-DC, DC and monocyte analysis ([Figures 5](#fig5){ref-type="fig"}A--5F), combined lin^-^HLA-DR^+^ cells were down-sampled to select 75,000 cells consisting of 20,000 CD11b^+^CD14^+^ monocytes, 4,000 CD11b^+^CD16^+^ monocytes and 50,000 non-monocyte cells. The concatenated .fcs file was subjected to tSNE dimension reduction with perplexity 30 from 1000 iterations using CD markers 14, 16, 123, 11b, 116, 303, 304, 2, 38, 10, 33, 11c, 90, 141, 34, 88, 117, 1c, 5 and Clec9A, AXL, SIGLEC6, SIRPA, IRF4, IRF8, FCER1A, and BTLA. tSNE plots and marker expression heat plots were generated in ggplot2 R package using tSNE co-ordinates exported from FlowJo.

### Diffusion maps and lineage tracing {#sec4.3.13}

cells were down-sampled using random sampling within FlowJo, according to the gating strategy in [Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C, to select a total of 14,000 cells consisting of up to 500 or 1000 cells per progenitor or precursor and mature cell population, respectively: GMP33^+^(300), GMP33^-^(200), CD123^lo-int^GMP(298), CD123^hi^303/4^lo^(499), CD2^+^pDC(490), pDC(490), early pre-DC2(498), pre-DC2(491), CD5^-^DC2(498), CD5^+^DC2(800), early pre-DC1(500), pre-DC1(254), cDC1(800), pre-DC3/mono(500), pre-DC3(298), CD14^-^DC3(498), CD14^+^DC3(1000), pre-mono(500), mono(999). Further analysis was undertaken in R version 3.6.0. Diffusion map calculation was performed with the destiny tool v 2.14.0 ([@bib4]) using log2-transformed values for the following CD markers: 14, 16, 123, 11b, 116, 303, 304, 2, 38, 10, 33, 11c, 90, 141, 34, 88, 117, 1c, 5, 15 and Clec9A, AXL, SIGLEC6, SIRPA, IRF4, IRF8, FCER1A, BTLA and FLT3. 3D graphics were produced with the rgl package v 0.100.30.

Quantification and Statistical Analysis {#sec4.4}
---------------------------------------

Graphs were plotted and statistical analyses performed with Prism 8 (GraphPad software Inc) or in R v3.3.3. Replicate numbers, p values and statistical tests are detailed in the figure legends.

Supplemental Information {#app2}
========================

Document S1. Tables S1--S4 and Figures S1--S7Data S1. 3D Diffusion Map of Single CD34^+^ Progenitor Cell Transcriptomes, Related to Figure 3HData and analysis shown in Figure 3H for interactive three-dimensional viewing: Single cell RNA-sequencing of 262 single cells from the CD34^+^progenitor subsets of BM. Diffusion map using all protein-coding, non-cell cycle genes to infer pseudo-temporal ordering of cells and reconstruct lineage branching. Cells are colored according to the hierarchical clusters generated in Figure S3JData S2. 3D Diffusion Map of Single DC Precursor Transcriptomes, Related to Figure 4HData and analysis shown in Figure 4H for interactive three-dimensional viewing: scRNA-Seq of 244 single cells sampled from CD34^neg-int^ pre-DC and mature DC populations of BM. Diffusion map generated with all protein-coding, non-cell cycle genes to infer pseudo-temporal ordering of cells and reconstruct lineage branching. Cells are colored according to the hierarchical clusters generated in Figure S4K.Data S3. 3D Diffusion Map of BM DC and Monocytes, Precursors, and Progenitors by CyTOF Analysis, Related to Figure 5FData and analysis shown in Figure 5F for interactive three-dimensional viewing: CyTOF analysis of FACS-purified CD45^+^lin(CD3, 19, 20, 56, 161)^-^ PB and BM progenitors, precursors and mature DC and monocytes using a panel of 33 surface antigens and 2 intracellular stains (IRF4 and IRF8). Two distinct CD45^+^ metal conjugates were used to stain PBMC and BMMC (allowing segregation of cells by tissue origin), before combining for further preparation. Diffusion map generated with 14,000 GMP, precursor and mature DC and monocyte cells to infer pseudo-temporal ordering of cells and reconstruct lineage branching. Populations were identified and color-coded according to the gating strategies in Figures 3A (progenitors) and 4A (precursors, DC and monocytes), applied to CyTOF data as shown in Figures S5B and S5C.Document S2. Article plus Supplemental Information
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